<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2013.00162</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Review Article</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Immune Mechanisms in Atherosclerosis, Especially in Diabetes Type 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Frosteg&#x000E5;rd</surname> <given-names>Johan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/79085"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Gabriel Virella, Faculdade de Medicina, Universidade de Lisboa, Portugal</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Susanna Hofmann, University of Cincinnati, USA; Gabriel Virella, Universidade de Lisboa, Portugal</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Johan Frosteg&#x000E5;rd, Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Scheeles v1, 17177 Stockholm, Sweden e-mail: <email>johan.frostegard&#x00040;ki.se</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Systems and Translational Endocrinology, a section of the journal Frontiers in Endocrinology.</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>10</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="collection">
<year>2013</year>
</pub-date><volume>4</volume>
<elocation-id>162</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>02</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>10</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013 Frosteg&#x000E5;rd.</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Atherosclerosis and ensuing cardiovascular disease (CVD) are major complications of diabetes type 2. Atherosclerosis is a chronic inflammatory condition involving immunocompetent cells of different types present in the lesions. Even though inflammation and immune activation may be more pronounced in atherosclerosis in diabetes type 2, there does not appear to be any major differences between diabetics and non-diabetics. Similar factors are thus implicated in atherosclerosis-associated immune activation in both groups. The cause of immune activation is not known and different mutually non-exclusive possibilities exist. Oxidized and/or enzymatically modified forms of low-density lipoprotein (OxLDL) and dead cells are present in atherosclerotic plaques. OxLDL could play a role, being pro-inflammatory and immunostimulatory as it activates T-cells and is cytotoxic at higher concentrations. Inflammatory phospholipids in OxLDL are implicated, with phosphorylcholine (PC) as one of the exposed antigens. Antibodies against PC (anti-PC) are anti-atherogenic in mouse studies, and anti-PC is negatively associated with development of atherosclerosis and CVD in humans. Bacteria and virus have been discussed as potential causes of immune activation, but it has been difficult to find direct evidence supporting this hypothesis, and antibiotic trials in humans have been negative or inconclusive. Heat shock proteins (HSP) could be one major target for atherogenic immune reactions. More direct causes of plaque rupture include cytokines such as interleukin 1&#x003B2; (IL-1&#x003B2;), tumor necrosis factor (TNF), and also lipid mediators as leukotrienes. In addition, in diabetes, hyperglycemia and oxidative stress appear to accelerate the development of atherosclerosis, one mechanism could be via promotion of immune reactions. To prove that immune reactions are causative of atherosclerosis and CVD, further studies with immune-modulatory treatments are needed.</p>
</abstract>
<kwd-group>
<kwd>atherosclerosis</kwd>
<kwd>immune system</kwd>
<kwd>natural antibodies</kwd>
<kwd>phospholipids</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="170"/>
<page-count count="11"/>
<word-count count="10864"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Background</title>
<p>Type 2 diabetes represents a major and growing problem throughout the world, not only in so-called developed countries. In addition to nephropathy and microvascular disease, cardiovascular disease (CVD), and accelerated atherosclerosis often occur in diabetes, both type 1 and 2 (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>). The main focus of this review is immune activation in atherosclerosis, especially in type 2 diabetes.</p>
<p>The link between type 2 diabetes and inflammation is well established, and there are signs of chronic inflammation in both diabetes and insulin resistance (IR), a typical feature of type 2 diabetes (<xref ref-type="bibr" rid="B4">4</xref>). Also in atherosclerosis and CVD, chronic inflammation is a major feature, and in atherosclerosis, activated immune competent cells such as T-cells and antigen-presenting cells, are abundant in lesions (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Even though inflammation and size of the necrotic core may be increased in atherosclerosis in diabetes (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>), there was no difference in the prevalence of macrophages, lymphocytes, and overall inflammation in plaque or in the atherosclerotic cap between diabetics and non-diabetics according to the largest study in this area (<xref ref-type="bibr" rid="B8">8</xref>). It thus appears that there is no known fundamental difference between the immune activation and inflammation present in atherosclerosis among non-diabetics as compared to diabetics. Still macrophages and surface thrombi may persist longer after ischemic symptoms in diabetes, which could contribute to the increased risk of recurrent CVD in this condition (<xref ref-type="bibr" rid="B8">8</xref>) and risk factors as hyperglycemia naturally play a special role. In this review, I therefore discuss immune activation in atherosclerosis in general and in diabetes type 2 in the same context.</p>
<p>Acute inflammatory response developed from an evolutionary point of view most likely to protect against pathogens and to repair tissue damage, which could be caused also by trauma. The classic symptoms of acute inflammation &#x02013; pain, swelling, redness, heat, and decrease of function &#x02013; were described already in Hippocratic medicine. When acute inflammation is not resolved, but instead persists and becomes chronic, it can become a major problem. Indeed chronic inflammatory conditions represent a major disease burden in the western world, and increasingly, also in developing countries (<xref ref-type="bibr" rid="B9">9</xref>). Examples of chronic inflammatory diseases include rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE); atherosclerosis and its major consequence, CVD including myocardial infarction (MI), acute coronary syndrome (ACS), claudication, and stroke; Alzheimer&#x02019;s disease; diabetes type 2; increased IR and even abdominal obesity and osteoarthritis have inflammatory components (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>Associations between these conditions are well known. For example, type 2 diabetes is a major risk factor for atherosclerosis and CVD (together with smoking, hypertension, dyslipidemia, age, and male sex) (<xref ref-type="bibr" rid="B10">10</xref>). Alzheimer&#x02019;s disease and atherosclerosis and/or CVD have some risk factors in common (<xref ref-type="bibr" rid="B11">11</xref>) and smoking is a risk marker for RA in addition to well known effects in CVD (<xref ref-type="bibr" rid="B12">12</xref>). It has also become clear that there are associations between rheumatic diseases and atherosclerosis/CVD, especially in SLE (<xref ref-type="bibr" rid="B13">13</xref>). Also in RA, there is an increased risk of CVD according to many reports, and a recent meta-analysis imply that atherosclerosis <italic>per se</italic> is more prevalent in patients in RA (<xref ref-type="bibr" rid="B13">13</xref>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>). It is interesting to note that there are reports which also describe an increased risk of type 2 diabetes in RA (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Anti-inflammatory treatments have improved the prognoses of many patients in chronic inflammatory conditions, the most notable example being biologics such as tumor necrosis factor (TNF)-inhibitors in RA and other autoimmune conditions (<xref ref-type="bibr" rid="B9">9</xref>). There is therefore an apparent need to evaluate targeted anti-inflammatory and immunomodulative treatments in other chronic inflammatory conditions.</p>
<p>An interesting possibility would be that biologics such as TNF-inhibitors could be therapeutically effective in atherosclerosis and diabetes type 2 and their complications. However, this does not appear to be the case to any significant degree. Although systemic blockade of TNF has an anti-cachectic effect in RA patients, the data on anti-TNF effects of IR are conflicting, depending on disease severity and degree of inflammation (<xref ref-type="bibr" rid="B17">17</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>). Still, a recent case report indicates that treatment with a novel T-cell inhibitor had a dramatic effect on IR in RA (<xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>As discussed in an editorial (<xref ref-type="bibr" rid="B14">14</xref>), it is interesting to note that inflammatory nature of atherosclerosis was known already 180&#x02009;years ago, reported by the famous Austrian pathologist K. Rokitansky. R. Virchow confirmed these findings somewhat later, and the ensuing debate between these two giants in the history of medicine is of interest also now (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Rokitansky argued that atherosclerosis is secondary to other disease processes and phenomena, while Virchow supported the view that inflammation in atherosclerosis is a primary pathogenic factor (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Both could be right, since atherosclerosis is nowadays recognized as an inflammatory process, and could be secondary to other inflammatory conditions.</p>
<p>A role of the immune system in atherosclerosis, with or without background of diabetes type 2, has been suggested since the 1980s, when activated T-cells were detected in human atherosclerotic lesions (<xref ref-type="bibr" rid="B23">23</xref>). Since then, an array of data indicate that immune activation is a major feature of and plays a role in atherosclerosis, and also that immunomodulation to ameliorate disease development could be an interesting possibility (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>At an early stage of atherosclerosis, macrophages accumulate and become filled with lipids, mainly derived from modified forms of low-density lipoprotein (LDL). These lipid-filled macrophages develop into foam cells, and subsequently, these and other cells die, creating a necrotic core of cell debris. An organized apoptotic clearance, is thus not effective in advanced atherosclerotic lesions. Also lymphocytes, especially T-cells, are common at a very early stage of disease development. In the 1990s, it was demonstrated that immunomodulation can change the course of atherosclerosis development; while administration of heat shock protein 60/65 accelerated atherosclerosis development (<xref ref-type="bibr" rid="B26">26</xref>), immunization with oxLDL, had the opposite effect (<xref ref-type="bibr" rid="B27">27</xref>).</p>
<p>However, it should be noted, that there may be important differences between animal models and human disease in this context (<xref ref-type="bibr" rid="B28">28</xref>). Even though mouse models of atherosclerosis have very much increased our understanding of atherosclerosis it is still interesting to note that there may be problems with translating mouse data to humans. For example, lipid levels are strikingly much higher in mice models, and another problem is that it is difficult to mimic human CVD in animal models, including mice models (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). In this review, I have therefore chosen to emphasize data on immunity and atherosclerosis which are derived from human studies, including <italic>ex vivo</italic> and cohort studies.</p>
<p>As discussed in a previous review (<xref ref-type="bibr" rid="B24">24</xref>), available evidence indicates that atherosclerosis <italic>per se</italic> is a normal part of human aging, though its complications may not be part of the normal aging process, at least not to the same extent.</p>
<p>A direct causative role played by T-cells is suggested by animal experiments, with transfer of beta(2)-glycoprotein I-reactive lymphocytes, which enhanced early atherosclerosis in LDL receptor-deficient mice (<xref ref-type="bibr" rid="B31">31</xref>). Further, CD4&#x0002B; T cells reactive to modified low-density lipoprotein aggravate atherosclerosis (<xref ref-type="bibr" rid="B32">32</xref>). An immunomodulatory role of T-cells is suggested by experiments where regulatory T cells suppress immune activation and thereby inhibit atherosclerosis (<xref ref-type="bibr" rid="B33">33</xref>). Interestingly, also NK T-cells may play a role in this context since CD1d-dependent activation of NKT cells aggravates atherosclerosis (<xref ref-type="bibr" rid="B34">34</xref>). Relatively little is known about the role of T-cells in human atherosclerosis, but it is interesting to note that Th17/Th1 imbalances have been reported, which may be related to plaque rupture (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Interestingly, data in humans and mice provide support for the concept that TH17 cells induced upon TGF-b signaling promote the development of cap structures in atherosclerotic plaques and the role of T-cells could depend on the local activation pattern and milieu (<xref ref-type="bibr" rid="B37">37</xref>). Clearly, the role of T-cells in plaque rupture is complicated. Further, subsets of T-lymphocytes with pro-atherogenic and plaque-destabilizing properties are increased in diabetes type 2 and associated with a worse CVD-outcome (<xref ref-type="bibr" rid="B38">38</xref>).</p>
<p>During recent years, a more detailed picture also of other inflammatory and/or immune competent cells has emerged from <italic>in vivo</italic> and other experimental studies, which need to be corroborated in human disease.</p>
<p>One example is dendritic cells (DC) which are specialized antigen-presenting cells, which may play an important role in the initiation and progression of atherosclerosis (<xref ref-type="bibr" rid="B39">39</xref>). DC are present in immature forms in the arterial wall and become activated during atherogenesis. In human atherosclerosis, DC are present both at an early stage (<xref ref-type="bibr" rid="B40">40</xref>) and late stage, with higher numbers in vulnerable plaques (<xref ref-type="bibr" rid="B41">41</xref>). Similar findings have been reported in mice, where DC may promote atherogenesis (<xref ref-type="bibr" rid="B42">42</xref>). Further, DC and T-cells co-localize in plaques (<xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>Monocytes/macrophages are present in lesions at different stages of atherosclerosis. Macrophages play a major role in inflammatory responses and may alter their phenotype which may vary on a scale, from pro-inflammatory M1 to anti-inflammatory M2 macrophages. Interestingly, even though the whole spectra of macrophages are present in lesions, including the relatively inert and surprisingly long lived macrophage-derived foam cells, M1 cells are prevalent in the vicinity of plaque rupture (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>Another cell type common in atherosclerotic lesions with inflammatory and potentially immune-modulatory properties is mast cells (<xref ref-type="bibr" rid="B46">46</xref>). A significant role played by this cell type in atherosclerosis and its complications is suggested by a recent report, where it is demonstrated that intraplaque mast cell numbers associate with future cardiovascular events (<xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>Even though some B-cells, neutrophils, and NK-cells are present in lesions, it is not known to what extent they play a major role (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>The role of the immune system in human atherosclerosis with or without background of diabetes type 2 is less defined as compared to the relevant animal models. T-cell reactive to OxLDL and related lipids are present in blood and atherosclerotic plaques (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>), patients with autoimmune diseases have increased atherosclerosis (<xref ref-type="bibr" rid="B13">13</xref>), and aspects of humoral immunity as natural antibodies against phosphorylcholine (PC) and other antigens are associated with atheroprotection (<xref ref-type="bibr" rid="B50">50</xref>). Humoral immunity has been shown to have pathogenic consequences in type 1 diabetes, triggered by immune complexes containing oxidized forms of LDL (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>Available data thus imply that the immune system plays a major role in atherosclerosis, which could be seen as a chronic inflammatory disease or disease process. Interestingly, also diabetes, IR abdominal obesity, and the metabolic syndrome also have important inflammatory components.</p>
</sec>
<sec id="S2">
<title>Diabetes and Causes of Immune Activation in Atherosclerosis</title>
<p>The key question herein is to elucidate what is the direct cause of the immune reactions in atherosclerosis, in general and in diabetes, and also how the inflammatory disease process can be influenced. There are several major hypotheses, non-mutually exclusive.</p>
<sec id="S2-1">
<title>Oxidation and other modifications of LDL and other moieties</title>
<p>Low-density lipoprotein can be modified by oxidation and/or enzymatic modification phospholipases being one example. LDL is also normally present in tissues as the intima of arteries, where it can bind to the proteoglycan matrix especially after modification. This binding is thought to be an early event in atherogenesis according to the &#x0201C;response to retention&#x0201D; hypothesis (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>).</p>
<p>Oxidized low-density lipoprotein has pro-inflammatory and immune-activating properties, activating endothelial cells, monocytes/macrophages, and T cells (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). OxLDL also toxic at higher concentrations and an important feature of atherosclerotic lesions, perhaps somewhat understudied, is the abundance of dead cells. It is thus possible that OxLDL is one cause of such cell death (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Enzymatically modified LDL could play a major role, and PLA2, which causes such modification, is expressed in both normal arteries and atherosclerotic lesions (<xref ref-type="bibr" rid="B56">56</xref>) and can induce activation of DC (<xref ref-type="bibr" rid="B57">57</xref>). Inflammatory phospholipids such as lysophosphatidylcholine (LPC) and/or platelet activating factor (PAF)-like lipids cause much of OxLDL:s effects which can occur through the PAF-receptor (<xref ref-type="bibr" rid="B58">58</xref>&#x02013;<xref ref-type="bibr" rid="B61">61</xref>) or other mechanisms including Toll-like receptor- and scavenger receptor-interaction (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>).</p>
<p>In general oxidized phospholipids (OxPL) are implicated in immune reactivity in atherosclerosis, and could be derived from LDL-modification but also from cell membrane changes. Such oxPL include LPC, and often, a shortened sn-2 position in the fatty acid moiety serves as a danger-associated molecular patterns (DAMP). Oxidation turns OxPLs into markers of modified self, which are recognized by both soluble and cell bound receptors such as scavenger receptors, natural antibodies, and also C-reactive protein (CRP). The common theme in these different system is likely to be removal of senescent and dead cells, but also oxidized or otherwise modified lipoproteins. This has been described in several recent publications (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B64">64</xref>&#x02013;<xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>Another important example of DAMP, in addition to PC and oxPL epitopes, is malonyl-dialdehyde (MDA) which is also generated during LDL-oxidation. MDA forms adducts on proteins, carbohydrates, and DNA (<xref ref-type="bibr" rid="B63">63</xref>).</p>
<p>Other compounds which could be implicated as atherogenic in OxLDL are modified and/or oxidized forms of apoB and cholesterol. Such modified compounds may play a role but the underlying mechanisms need to be better defined (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B70">70</xref>). Clinical studies support the hypothesis of inflammatory phospholipids as causes of atherosclerosis, whereas levels of OxLDL are raised in the metabolic syndrome (<xref ref-type="bibr" rid="B71">71</xref>), in hypertension (<xref ref-type="bibr" rid="B72">72</xref>) and in established type 2 diabetes (<xref ref-type="bibr" rid="B73">73</xref>). Further, high levels of MDA-LDL in isolated immune complexes predict future MI and acute CVD events in patients with type 2 diabetes (<xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>Many epidemiological studies demonstrate that smoking is associated with atherosclerosis and CVD (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>) and animal experiments demonstrate that smoking promotes atherogenesis (<xref ref-type="bibr" rid="B77">77</xref>&#x02013;<xref ref-type="bibr" rid="B79">79</xref>). Somewhat surprisingly, underlying mechanisms are not fully clarified. Still, one mechanism is smoking-induced increased lipid-oxidation (<xref ref-type="bibr" rid="B80">80</xref>) and closely related to this, oxidative stress (<xref ref-type="bibr" rid="B81">81</xref>). Smoking is associated with systemic and local inflammation with raised levels of pro-inflammatory cytokines and cells, in particular in chronic obstructive pulmonary disease (<xref ref-type="bibr" rid="B82">82</xref>), which could play a role also in atherosclerosis.</p>
<p>Additionally, several factors appear to be diabetes-specific and able to further aggravate atherosclerosis (and CVD) among diabetics. One major such factor is reduction of endothelial nitric oxide (NO)-levels, leading to deterioration of endothelial function, an early sign of vascular problems and increased risk of atherosclerosis and CVD. Hyperglycemia <italic>per se</italic> leads to increased levels of reactive oxygen species, which in turn inactivate NO and thus impair endothelial function. One common denominator is the formation of advanced glycation end products (AGEs) which have pro-inflammatory and potentially atherogenic properties (<xref ref-type="bibr" rid="B83">83</xref>&#x02013;<xref ref-type="bibr" rid="B88">88</xref>). Interestingly, atherosclerosis is suppressed by the soluble receptor for AGEs in an animal model (<xref ref-type="bibr" rid="B89">89</xref>). Also susceptibility of LDL and its subfractions to glycation could play a role, in diabetes type 2 (<xref ref-type="bibr" rid="B90">90</xref>) AGE-products of LDL are able to generate autoantibodies, which on the other hand appear to have pro-inflammatory properties (<xref ref-type="bibr" rid="B91">91</xref>). Another interesting connection between AGEs and OxLDL are previous findings where AGEs initiate LDL oxidation (<xref ref-type="bibr" rid="B92">92</xref>). Further, increased oxidation of LDL in diabetes could promote atherogenesis (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B93">93</xref>).</p>
<p>Other potential underlying factors are present in type 2 diabetes, but where the connection to immune reactivity in atherosclerosis is less clear, and thus not a focus herein. These include increased circulating free fatty acids in patients with abdominal obesity, which could be atherogenic by decreasing HDL-levels, increasing levels of small dense LDL and also by a negative effect on endothelial function (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B94">94</xref>). Other mechanisms include effects on smooth muscle cells, such as induction of apoptosis and thus plaque instability (<xref ref-type="bibr" rid="B95">95</xref>) and also a hypercoagulative state by alterations in platelet function (<xref ref-type="bibr" rid="B96">96</xref>).</p>
</sec>
<sec id="S2-2">
<title>Autoantibodies and immune complexes related to phospholipid epitopes and OxLDL</title>
<p>An interesting possibility is that immune complexes containing OxLDL could contribute to vascular damage by promoting inflammation and atherosclerosis, which has been reported in type 2 diabetes (<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B98">98</xref>). In addition to oxLDL, also MDA-LDL and AGE-product-modified LDL induce immune responses in humans (<xref ref-type="bibr" rid="B99">99</xref>). The role of antibodies against these different forms of modified LDL is less clear, and varies in different studies: both negative and positive associations have been described. This could depend on different methods used, different degrees of oxidation and also on different immunoglobulin subclasses and isotypes. On the other hand, the antigenic constitution of immune complexes formed with modified forms of LDL and their corresponding antibodies may influence their pathogenicity, as suggested by the recent observation that high levels of highly oxidized forms of LDL (MDA-LDL) in isolated IC predict future MI and acute CV events in patients with type 2 diabetes (<xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>It is also possible that there are differences between mouse and man which could be the basis for the conflicting views about the pathogenic or protective role of the antibody response to modified forms of LDL (<xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B101">101</xref>).</p>
<p>Another type of antibodies that has attracted attention are those against PC (anti-PC), which are often considered as &#x0201C;natural&#x0201D; antibodies. We have reported in several publications that anti-PC is a protection marker for atherosclerosis development and CVD, in different populations, both healthy individuals, ACS patients, and patients with SLE or RA (<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B102">102</xref>&#x02013;<xref ref-type="bibr" rid="B107">107</xref>). Animal experiments also support a protective role of anti-PC. Immunization with pneumococci containing PC induced a decrease in atherosclerosis development in a mouse model in parallel with an increase in anti-PC, among other antibodies (<xref ref-type="bibr" rid="B108">108</xref>). Passive and active immunization raising anti-PC levels decrease atherosclerosis in mouse models (<xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>).</p>
<p>Human anti-PC could be anti-atherogenic and decrease risk of CVD by anti-inflammatory effects (<xref ref-type="bibr" rid="B107">107</xref>), inhibition of oxLDL-uptake through scavenger receptors (<xref ref-type="bibr" rid="B111">111</xref>) and inhibition of LPC-induced cell (<xref ref-type="bibr" rid="B112">112</xref>). In mouse models, the anti-inflammatory effect of anti-PC was confirmed, and facilitating phagocytosis was reported as one mechanism. Anti-PC antibodies bind dead and dying cells, enhancing their phagocytosis and clearance (<xref ref-type="bibr" rid="B113">113</xref>). Further investigations are necessary to determine whether the data generated in animal models translates to human medicine.</p>
<p>A Western life style could play a role to influence anti-PC levels, and one underlying factor could be infections which are not prevalent in developed countries (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B115">115</xref>). Gluten in the diet could also play a role being a novel component of human diet from an evolutionary point of view (<xref ref-type="bibr" rid="B116">116</xref>). The heritability of anti-PC is 37%, allowing also for genetic factors (<xref ref-type="bibr" rid="B117">117</xref>). In line with these findings, a recent report indicates that antibodies against reactive a-dicarbonyls such as methylglyoxal (MGO) are negatively associated with atherosclerosis development among patients with diabetes type 2. This finding suggests an additional role played by diabetes type 2 immune reactivity in atherosclerosis development as compared to the general population (<xref ref-type="bibr" rid="B118">118</xref>). Still, it is interesting to note that MGO-LDL is only weakly immunogenic in humans (<xref ref-type="bibr" rid="B119">119</xref>). Clearly, further research is needed to clarify the role by AGE-recognizing antibodies in diabetes type 2 and atherosclerosis.</p>
<p>A potential role of epigenetic changes in both atherosclerosis/CVD and type 2 diabetes is not the topic of this review, though a very interesting subject. One can not exclude that epigenetic mechanisms may influence immune mechanisms in both these conditions. In an intriguing study, it was recently demonstrated that in an atherosclerosis mouse model, maternal immunization with oxidized LDL affects <italic>in utero</italic> programing of both atherosclerosis and IR and type 2 diabetes, promoting protection against development of these conditions (<xref ref-type="bibr" rid="B120">120</xref>) Whether this can be translated to humans also remains to be demonstrated.</p>
</sec>
<sec id="S2-3">
<title>Heat shock proteins</title>
<p>Antibodies against heat shock proteins (HSPs), especially HSP60/65 but also others like HSP70 and HSP90 have been described as potential causes of atherosclerosis and CVD. HSPs are immunogenic, and T-cell clones recognizing HSP60 are present in atherosclerotic plaques (<xref ref-type="bibr" rid="B121">121</xref>, <xref ref-type="bibr" rid="B122">122</xref>). HSPs may activate immune reactions through cross-reactivity with HSP from microorganisms as bacteria. This is supported by both clinical data with associations between antibodies against HSP60/65 and atherosclerosis, and experimental data where immunization with HSP 60/65 increases atherosclerosis in an animal model (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B123">123</xref>).</p>
<p>We hypothesized that hypertension possibly could cause and immune reaction and inflammation in arteries by induction of HSP 60/65, which are also induced by oxLDL (<xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B125">125</xref>) and in principle, in conditions such as diabetes, where LDL-oxidation is implicated, this could further enhance the progression of atherosclerosis.</p>
</sec>
<sec id="S2-4">
<title>Infections</title>
<p>Infections have since long been hypothesized to be a cause of atherosclerosis. Many pathogenic candidates have been proposed, one not excluding another. <italic>Chlamydophila pneumoniae</italic> (CP); periodontal organisms including <italic>Porphyromonas gingivalis</italic> (PG) and <italic>Aggregatibacter actinomycetemcomitans</italic> (AA); <italic>Helicobacter pylori</italic> (HP) and Cytomegalovirus (CVM) are among the most promising candidates, since they are present in plaques, promote atherosclerosis in animal studies, and have associations with disease in humans (<xref ref-type="bibr" rid="B126">126</xref>).</p>
<p>Early studies demonstrated presence of CP in atherosclerotic plaques (<xref ref-type="bibr" rid="B127">127</xref>) and that antibodies against CP were associated with CVD (<xref ref-type="bibr" rid="B128">128</xref>&#x02013;<xref ref-type="bibr" rid="B130">130</xref>) but later also negative studies were published (<xref ref-type="bibr" rid="B126">126</xref>).</p>
<p>However, treatment with CP-targeting antibiotics had no effect on atherosclerosis (<xref ref-type="bibr" rid="B131">131</xref>&#x02013;<xref ref-type="bibr" rid="B133">133</xref>). This clearly argues against CP as a causative agent, though there could be other explanations, for example, CP is difficult to reach within the plaque and thus it is still possible that at the earlier stages of CP-infection antibacterial treatment could be beneficial (<xref ref-type="bibr" rid="B126">126</xref>).</p>
<p>Periodontal pathogens, as PG and AA, are also interesting pathogenic candidates. The association with periodontitis and CVD/atherosclerosis has been debated since there are confounders, including social ones, which may be difficult to control for. A recent statement from the American Heart Association supports an independent association between periodontal disease and atherosclerosis, but available data do not prove causation, even though it is interesting that intervention does decrease systemic inflammation and improves endothelial function (<xref ref-type="bibr" rid="B134">134</xref>).</p>
<p>Still it is interesting that periodontitis and diabetes could be related to each other, and in principle, periodontitis could be diabetogenic and then also increase the risk of atherosclerosis and CVD, while diabetes could increase the risk of periodontitis (<xref ref-type="bibr" rid="B135">135</xref>&#x02013;<xref ref-type="bibr" rid="B137">137</xref>).</p>
<p>An inherent problem with viral infections such as CMV from the Herpes virus group is that they are very common, thus making the interpretation of any associations with diabetes, atherosclerosis or CVD complicated. It may be that certain patients subgroups that are prone to accelerated atherosclerosis and CVD, as it is seen for example after organ transplantation, CMV infection plays an important role (<xref ref-type="bibr" rid="B138">138</xref>). CMV is present in atherosclerotic lesions in many but not all studies (<xref ref-type="bibr" rid="B126">126</xref>), but also in healthy arteries (<xref ref-type="bibr" rid="B139">139</xref>) so in principle CMV could be just an innocent by-stander. However, CMV induces migration of arterial smooth muscle cells <italic>in vitro</italic>, suggesting potential pro-atherogenic mechanisms (<xref ref-type="bibr" rid="B140">140</xref>).</p>
<p><italic>Helicobacter pylori</italic> infection, causing gastritis and gastric ulcer, may be implicated as supported by indirect evidence, where reduction of CVD after eradication of HP was reported (<xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B141">141</xref>). However, no viable HP had been isolated from atherosclerotic plaques, and mouse experiments in general do not support a pathogenic role of HP in atherosclerosis (<xref ref-type="bibr" rid="B142">142</xref>).</p>
<p>Other pathogens including HIV, EBV, influenza virus, <italic>Mycoplasma pneumoniae</italic> and <italic>Streptococcus pneumoniae</italic> have also been discussed, but as of yet there is no conclusive causative evidence available (<xref ref-type="bibr" rid="B126">126</xref>). Borreliosis caused by spirochetes, is independently associated with CVD, although little is known from atherosclerosis-related experimental studies (<xref ref-type="bibr" rid="B143">143</xref>).</p>
<p>It is not clear if infections on the diabetic background contribute more to atherosclerosis, but it is interesting to note that an increased rate of infections with <italic>Chlamydia pneumoniae</italic> has been reported in patients with diabetes type 2 (<xref ref-type="bibr" rid="B144">144</xref>).</p>
<p>Taken together, even though the infection hypothesis in atherosclerosis with or without diabetes type 2 is very interesting and is supported by circumstantial evidence, there is still little direct evidence of a potential causative or pathogenic role of microorganisms in CVD/atherosclerosis. However, we can not exclude a possibility that infectious agents act in concert with diabetes-specific factors to promote atherosclerosis.</p>
<p>Infections could also be of importance indirectly. Many pathogens are present in lesions, and could start or promote an ongoing local inflammatory process which could lead to increased atherosclerosis and, in principle, also to CVD and plaque rupture &#x02013; at such sites, the local inflammation appears to be especially strong (<xref ref-type="bibr" rid="B5">5</xref>). Also the total infectious burden is associated with increased atherosclerosis and CVD, and the risk of infection is raised in diabetes, especially when blood glucose levels are not well controlled. Platelet aggregation and endothelial dysfunction, could also influence atherogenesis in this context (<xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B145">145</xref>).</p>
</sec>
<sec id="S2-5">
<title>Other types of immune activation in diabetes type 2 and atherosclerosis</title>
<p>Another potential link between atherosclerosis and diabetes type 2, and thus also hyperglycemia and metabolic dysfunction, is provided by a recent study, where NKG2D, an immune-activating receptor expressed by different types of immune cells was tested (<xref ref-type="bibr" rid="B146">146</xref>). The authors reported that blocking NKG2D in apolipoprotein E-deficient (apo E<sup>&#x02212;/&#x02212;</sup>) mice led to a dramatic reduction in plaque formation, suppressed systemic and organ-specific inflammation, and improved abnormal metabolic conditions. Thus the NKG2D/ligand interaction could drive both: inflammation related to metabolic dysfunction/diabetes type 2 and atherosclerosis. Further, the molecules and pathogens discussed earlier such as OxLDL, HSPs, AGEs, and infectious agents, could upregulate NKG2D on different cell types, which in turn can activate T-cells, NK, and NKT cells and thus promote atherosclerosis; also other cell types as endothelial cells could produce pro-atherogenic factors, including cytokines (<xref ref-type="bibr" rid="B146">146</xref>).</p>
<p>It is well known that inflammation is a link between IR, obesity, and diabetes. Further abdominal obesity and IR are classic features of type 2 diabetes (<xref ref-type="bibr" rid="B147">147</xref>).</p>
<p>There are many examples of links between inflammation in other conditions and atherosclerosis. Periodontitis is also a systemic inflammatory condition, which is more frequent in patients with diabetes, could increase the risk of atherosclerosis and CVD also indirectly (<xref ref-type="bibr" rid="B137">137</xref>).</p>
<p>Raised levels of CRP is a risk marker for atherosclerosis and CVD in many studies, though it is not clear if CRP is either protective or detrimental for disease development. Cytokines as IL-6 and raised systemic levels of OxLDL are other examples of pro-inflammatory molecules that are associated with increased risk of CVD and atherosclerosis (<xref ref-type="bibr" rid="B10">10</xref>). Another group of inflammatory compounds that are present in advanced atherosclerotic plaques are lipid mediators, such as leukotrienes (<xref ref-type="bibr" rid="B148">148</xref>, <xref ref-type="bibr" rid="B149">149</xref>).</p>
<p>Another example of associations between systemic inflammation and atherosclerosis and CVD is a number of autoimmune diseases. The evidence is strongest for SLE, where the risk of CVD is very high (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B150">150</xref>). Also in RA and other types of autoimmune conditions, atherosclerosis is increased according to many studies including a recent meta-analysis (<xref ref-type="bibr" rid="B13">13</xref>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>).</p>
</sec>
</sec>
<sec id="S3">
<title>Treatment Against Inflammation and Immune Activation to Ameliorate Atherosclerosis, Decrease Risk of CVD, Especially in Diabetes</title>
<sec id="S3-6">
<title>Optimal diabetes treatment</title>
<p>Since diabetes type 2 is an inflammatory condition, first and foremost, control of the disease itself is likely of major importance for amelioration of pro-atherogenic inflammation and immune reactions. The specific optimal range of glycemic control in relation to CVD and atherosclerosis is still debated (<xref ref-type="bibr" rid="B151">151</xref>). This is similar to the situation in rheumatic diseases, where at least for RA, the risk may be similar to that in type 2 diabetes and where disease controls appears to be of importance (<xref ref-type="bibr" rid="B13">13</xref>).</p>
</sec>
<sec id="S3-7">
<title>Statins</title>
<p>Statins were developed to treat hyperlipidemia and are often used in diabetes, though there is still some controversy about their exact role in this condition (<xref ref-type="bibr" rid="B152">152</xref>). Interestingly, statins have additional anti-inflammatory effects rather than simply decreasing cholesterol levels, which could be of major importance in atherosclerosis and CVD, not least in diabetic patients. These properties could be seen as &#x0201C;side-effect&#x0201D; of HMG CoA-reductase inhibition. Interestingly, statins have immunomodulatory properties, such as impairment of CD1d-mediated antigen presentation through the inhibition of prenylation (<xref ref-type="bibr" rid="B153">153</xref>) and decreasing MHC class II interaction with antigen (<xref ref-type="bibr" rid="B154">154</xref>). Further, the lipid-lowering effect of statins could by itself influence the immune reactions to LDL-related antigens, since a decrease in LDL-levels is likely to decrease also exposure of the immune system to modified forms of LDL, thus reducing the intensity of the corresponding immune response.</p>
<p>The Jupiter study demonstrated that statin treatment may be beneficial for individuals with increased high sensitivity CRP but normal LDL and it is possible that the beneficial effects of statins to some extent are in fact caused by their anti-inflammatory and immune-modulatory properties (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B156">156</xref>).</p>
</sec>
<sec id="S3-8">
<title>Anti-inflammatory treatment</title>
<p>Even though the major focus of this review is immune activation it is still interesting to discuss this in the context of inflammation in general, especially in relation to treatment. There is as yet no established anti-inflammatory treatment of atherosclerosis or CVD, with or without diabetes. There are several interesting possibilities that are currently being investigated. In RA, treatment with methotrexate weekly is a very common schedule, and a recent meta-analysis demonstrate that the risk of CVD is decreased in patients with RA treated with methotrexate (<xref ref-type="bibr" rid="B157">157</xref>). Animal studies show that methotrexate decreases atherogenesis (<xref ref-type="bibr" rid="B158">158</xref>). In the cardiovascular inflammation reduction trial (CIRT) low dose methotrexate (target dose 20&#x02009;mg/week) is tested for reduction of CVD events among post-MI patients with diabetes or metabolic syndrome (<xref ref-type="bibr" rid="B156">156</xref>). There are different opinions about whether biologics as anti-TNF are beneficial from a cardiovascular point of view, though a recent study where decrease of CVD was reported in RA adds support to this possibility (<xref ref-type="bibr" rid="B159">159</xref>, <xref ref-type="bibr" rid="B160">160</xref>). The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) investigates interleukin-1&#x003B2; (IL-1&#x003B2;) inhibition and reduced risk of MI, stroke, and CVD in stable coronary artery disease patients with persistent elevations of CRP (&#x02265;2&#x02009;mg/L) (<xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B161">161</xref>).</p>
<p>Other interesting anti-inflammatory treatments could be inhibition of inflammatory lipid mediators as PAF (<xref ref-type="bibr" rid="B162">162</xref>). Annexin A5 is anti-thrombotic plasma protein, which is anti-inflammatory, inhibits atherosclerosis development and improves endothelial function in a mouse model (<xref ref-type="bibr" rid="B163">163</xref>). Annexin A5 could thus be a possible therapy candidate. Inhibition of phospholipases as treatment in patients after ACS are currently in trials (<xref ref-type="bibr" rid="B164">164</xref>).</p>
</sec>
<sec id="S3-9">
<title>Immunomodulatory therapy</title>
<p>Studies in mid-90s demonstrated that immunization with modified forms of LDL ameliorated atherosclerosis in animal models (<xref ref-type="bibr" rid="B27">27</xref>), providing initial evidence for immunomodulation as a potential treatment against atherosclerosis. One line of treatment is to target the apoB components which decreases atherosclerosis development in animal models (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B165">165</xref>). However, such treatment did not show positive expected effect in humans (<xref ref-type="bibr" rid="B166">166</xref>), though the possibility that the end points used in this study where not optimal cannot be excluded.</p>
<p>Another possibility is that the phospholipid moiety on OxLDL could be the basis of immunomodulation, one example being PC. This is supported by clinical studies, animal and <italic>in vitro</italic> experiments (<xref ref-type="bibr" rid="B50">50</xref>). As discussed, mechanisms include anti-inflammatory (<xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B167">167</xref>), inhibition of cell death (<xref ref-type="bibr" rid="B112">112</xref>), and decreased uptake of oxLDL in macrophages (<xref ref-type="bibr" rid="B105">105</xref>). Further, administration of immunoglobulins has shown promising results in animal studies (<xref ref-type="bibr" rid="B168">168</xref>). Another interesting possibility is to ameliorate atherosclerosis by modulating immune reactions against HSP (<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B170">170</xref>).</p>
</sec>
</sec>
<sec id="S4">
<title>Summary and Conclusion</title>
<p>Taken together, atherosclerosis and ensuing CVD represents major health problems in the developed world and especially so in patients with diabetes, where macro-vascular complications is a common problem. It has become clear that atherosclerosis on a background of diabetes or without is a chronic inflammation characterized by presence of activated immune competent cells throughout the lesions. Atherosclerosis in diabetes, though accelerated, does not seem to be very different from atherosclerosis in individuals without diabetes type 2, although certain diabetes-specific factors could contribute to pro-atherogenic immune activation and thus aggravate atherosclerosis and risk of CVD. In diabetes, reduction of endothelial NO-levels, systemic hyperglycemia if uncontrolled, generation of reactive oxygen species, oxidative stress, and increased LDL-oxidation, formation of AGEs, and increased circulating free fatty acids are factors that add to atherosclerosis and CVD risk. Potential triggers of immune activation in atherosclerosis in the general population (as well as among diabetics) include OxLDL and other LDL modifications and corresponding antibodies, possibly infections, high levels of heat shock protein antibodies, and low levels of natural antibodies as anti-PC. Clinical trials and other studies of immune-modulatory and anti-inflammatory treatment in atherosclerosis and CVD are currently conducted but until such treatments are proven to be effective in humans, the exact role of immune reactions and inflammation in human atherosclerosis with or without type 2 diabetes remains to be clarified.</p>
</sec>
<sec id="S5">
<title>Conflict of Interest Statement</title>
<p>I am named as inventor on patent and patent applications relating to immunity and phospholipid antigens.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname> <given-names>JA</given-names></name> <name><surname>Creager</surname> <given-names>MA</given-names></name> <name><surname>Libby</surname> <given-names>P</given-names></name></person-group>. <article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title>. <source>JAMA</source> (<year>2002</year>) <volume>287</volume>(<issue>19</issue>):<fpage>2570</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1001/jama.287.19.2570</pub-id><pub-id pub-id-type="pmid">12020339</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y</given-names></name> <name><surname>Lu</surname> <given-names>B</given-names></name> <name><surname>Sun</surname> <given-names>ML</given-names></name> <name><surname>Hou</surname> <given-names>ZH</given-names></name> <name><surname>Yu</surname> <given-names>FF</given-names></name> <name><surname>Cao</surname> <given-names>HL</given-names></name> <etal/></person-group> <article-title>Comparison of atherosclerotic plaque by computed tomography angiography in patients with and without diabetes mellitus and with known or suspected coronary artery disease</article-title>. <source>Am J Cardiol</source> (<year>2011</year>) <volume>108</volume>(<issue>6</issue>):<fpage>809</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2011.04.032</pub-id><pub-id pub-id-type="pmid">21741605</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname> <given-names>R</given-names></name> <name><surname>Kataoka</surname> <given-names>Y</given-names></name> <name><surname>Uno</surname> <given-names>K</given-names></name> <name><surname>Nicholls</surname> <given-names>SJ</given-names></name></person-group>. <article-title>The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights</article-title>. <source>Curr Diab Rep</source> (<year>2012</year>) <volume>12</volume>(<issue>3</issue>):<fpage>280</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1007/s11892-012-0270-y</pub-id><pub-id pub-id-type="pmid">22492060</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname> <given-names>NG</given-names></name> <name><surname>Sousa</surname> <given-names>LP</given-names></name> <name><surname>Sousa</surname> <given-names>MO</given-names></name> <name><surname>Pietrani</surname> <given-names>NT</given-names></name> <name><surname>Fernandes</surname> <given-names>AP</given-names></name> <name><surname>Gomes</surname> <given-names>KB</given-names></name></person-group>. <article-title>The linkage between inflammation and Type 2 diabetes mellitus</article-title>. <source>Diabetes Res Clin Pract</source> (<year>2013</year>) <volume>99</volume>(<issue>2</issue>):<fpage>85</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1016/j.diabres.2012.09.003</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Ulfgren</surname> <given-names>AK</given-names></name> <name><surname>Nyberg</surname> <given-names>P</given-names></name> <name><surname>Hedin</surname> <given-names>U</given-names></name> <name><surname>Swedenborg</surname> <given-names>J</given-names></name> <name><surname>Andersson</surname> <given-names>U</given-names></name> <etal/></person-group> <article-title>Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines</article-title>. <source>Atherosclerosis</source> (<year>1999</year>) <volume>145</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/S0021-9150(99)00011-8</pub-id><pub-id pub-id-type="pmid">10428293</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purushothaman</surname> <given-names>KR</given-names></name> <name><surname>Purushothaman</surname> <given-names>M</given-names></name> <name><surname>Muntner</surname> <given-names>P</given-names></name> <name><surname>Lento</surname> <given-names>PA</given-names></name> <name><surname>O&#x02019;Connor</surname> <given-names>WN</given-names></name> <name><surname>Sharma</surname> <given-names>SK</given-names></name> <etal/></person-group> <article-title>Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis</article-title>. <source>Vasc Med</source> (<year>2011</year>) <volume>16</volume>(<issue>2</issue>):<fpage>103</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1177/1358863X11402249</pub-id><pub-id pub-id-type="pmid">21511672</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname> <given-names>AP</given-names></name> <name><surname>Kolodgie</surname> <given-names>FD</given-names></name> <name><surname>Zieske</surname> <given-names>A</given-names></name> <name><surname>Fowler</surname> <given-names>DR</given-names></name> <name><surname>Weber</surname> <given-names>DK</given-names></name> <name><surname>Varghese</surname> <given-names>PJ</given-names></name> <etal/></person-group> <article-title>Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2004</year>) <volume>24</volume>(<issue>7</issue>):<fpage>1266</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.0000131783.74034.97</pub-id><pub-id pub-id-type="pmid">15142859</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redgrave</surname> <given-names>JN</given-names></name> <name><surname>Lovett</surname> <given-names>JK</given-names></name> <name><surname>Syed</surname> <given-names>AB</given-names></name> <name><surname>Rothwell</surname> <given-names>PM</given-names></name></person-group>. <article-title>Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study)</article-title>. <source>Cerebrovasc Dis</source> (<year>2008</year>) <volume>26</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1159/000136900</pub-id><pub-id pub-id-type="pmid">18535373</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tabas</surname> <given-names>I</given-names></name> <name><surname>Glass</surname> <given-names>CK</given-names></name></person-group>. <article-title>Anti-inflammatory therapy in chronic disease: challenges and opportunities</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>(<issue>6116</issue>):<fpage>166</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1126/science.1230720</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname> <given-names>P</given-names></name> <name><surname>Ridker</surname> <given-names>PM</given-names></name> <name><surname>Hansson</surname> <given-names>GK</given-names></name></person-group>. <article-title>Progress and challenges in translating the biology of atherosclerosis</article-title>. <source>Nature</source> (<year>2011</year>) <volume>473</volume>(<issue>7347</issue>):<fpage>317</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1038/nature10146</pub-id><pub-id pub-id-type="pmid">21593864</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahathevan</surname> <given-names>R</given-names></name> <name><surname>Brodtmann</surname> <given-names>A</given-names></name> <name><surname>Donnan</surname> <given-names>GA</given-names></name></person-group>. <article-title>Dementia, stroke, and vascular risk factors; a review</article-title>. <source>Int J Stroke</source> (<year>2012</year>) <volume>7</volume>(<issue>1</issue>):<fpage>61</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1111/j.1747-4949.2011.00731.x</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kallberg</surname> <given-names>H</given-names></name> <name><surname>Ding</surname> <given-names>B</given-names></name> <name><surname>Padyukov</surname> <given-names>L</given-names></name> <name><surname>Bengtsson</surname> <given-names>C</given-names></name> <name><surname>Ronnelid</surname> <given-names>J</given-names></name> <name><surname>Klareskog</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke</article-title>. <source>Ann Rheum Dis</source> (<year>2011</year>) <volume>70</volume>(<issue>3</issue>):<fpage>508</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1136/ard.2009.120899</pub-id><pub-id pub-id-type="pmid">21149499</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Atherosclerosis in patients with autoimmune disorders</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2005</year>) <volume>25</volume>(<issue>9</issue>):<fpage>1776</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.0000174800.78362.ec</pub-id><pub-id pub-id-type="pmid">15976324</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Cardiovascular co-morbidity in patients with rheumatic diseases</article-title>. <source>Arthritis Res Ther</source> (<year>2011</year>) <volume>13</volume>(<issue>3</issue>):<fpage>225</fpage>.<pub-id pub-id-type="doi">10.1186/ar3326</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tyrrell</surname> <given-names>PN</given-names></name> <name><surname>Beyene</surname> <given-names>J</given-names></name> <name><surname>Feldman</surname> <given-names>BM</given-names></name> <name><surname>McCrindle</surname> <given-names>BW</given-names></name> <name><surname>Silverman</surname> <given-names>ED</given-names></name> <name><surname>Bradley</surname> <given-names>TJ</given-names></name></person-group>. <article-title>Rheumatic disease and carotid intima-media thickness. A systematic review and meta-analysis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2010</year>) <volume>30</volume>(<issue>5</issue>):<fpage>1014</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.109.198424</pub-id><pub-id pub-id-type="pmid">20150560</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wasko</surname> <given-names>MC</given-names></name> <name><surname>Kay</surname> <given-names>J</given-names></name> <name><surname>Hsia</surname> <given-names>EC</given-names></name> <name><surname>Rahman</surname> <given-names>MU</given-names></name></person-group>. <article-title>Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease</article-title>. <source>Arthritis Care Res (Hoboken)</source> (<year>2011</year>) <volume>63</volume>(<issue>4</issue>):<fpage>512</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1002/acr.20414</pub-id><pub-id pub-id-type="pmid">21452264</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>CP</given-names></name> <name><surname>Oeser</surname> <given-names>A</given-names></name> <name><surname>Solus</surname> <given-names>JF</given-names></name> <name><surname>Gebretsadik</surname> <given-names>T</given-names></name> <name><surname>Shintani</surname> <given-names>A</given-names></name> <name><surname>Avalos</surname> <given-names>I</given-names></name> <etal/></person-group> <article-title>Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms</article-title>. <source>Arthritis Rheum</source> (<year>2008</year>) <volume>58</volume>(<issue>7</issue>):<fpage>2105</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1002/art.23600</pub-id><pub-id pub-id-type="pmid">18576352</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Gay</surname> <given-names>MA</given-names></name> <name><surname>De Matias</surname> <given-names>JM</given-names></name> <name><surname>Gonzalez-Juanatey</surname> <given-names>C</given-names></name> <name><surname>Garcia-Porrua</surname> <given-names>C</given-names></name> <name><surname>Sanchez-Andrade</surname> <given-names>A</given-names></name> <name><surname>Martin</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis</article-title>. <source>Clin Exp Rheumatol</source> (<year>2006</year>) <volume>24</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">16539824</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferraz-Amaro</surname> <given-names>I</given-names></name> <name><surname>Arce-Franco</surname> <given-names>M</given-names></name> <name><surname>Muniz</surname> <given-names>J</given-names></name> <name><surname>Lopez-Fernandez</surname> <given-names>J</given-names></name> <name><surname>Hernandez-Hernandez</surname> <given-names>V</given-names></name> <name><surname>Franco</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Systemic blockade of TNF-alpha does not improve insulin resistance in humans</article-title>. <source>Horm Metab Res</source> (<year>2011</year>) <volume>43</volume>(<issue>11</issue>):<fpage>801</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1055/s-0031-1287783</pub-id><pub-id pub-id-type="pmid">22009376</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ursini</surname> <given-names>F</given-names></name> <name><surname>Mauro</surname> <given-names>D</given-names></name> <name><surname>Naty</surname> <given-names>S</given-names></name> <name><surname>Gagliardi</surname> <given-names>D</given-names></name> <name><surname>Grembiale</surname> <given-names>RD</given-names></name></person-group>. <article-title>Improvement in insulin resistance after short-term treatment with abatacept: case report and short review</article-title>. <source>Clin Rheumatol</source> (<year>2012</year>) <volume>31</volume>(<issue>9</issue>):<fpage>1401</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1007/s10067-012-2034-0</pub-id><pub-id pub-id-type="pmid">22837017</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mayerl</surname> <given-names>C</given-names></name> <name><surname>Lukasser</surname> <given-names>M</given-names></name> <name><surname>Sedivy</surname> <given-names>R</given-names></name> <name><surname>Niederegger</surname> <given-names>H</given-names></name> <name><surname>Seiler</surname> <given-names>R</given-names></name> <name><surname>Wick</surname> <given-names>G</given-names></name></person-group>. <article-title>Atherosclerosis research from past to present &#x02013; on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow</article-title>. <source>Virchows Arch</source> (<year>2006</year>) <volume>449</volume>(<issue>1</issue>):<fpage>96</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1007/s00428-006-0176-7</pub-id><pub-id pub-id-type="pmid">16612625</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Rheumatic diseases: insights into inflammation and atherosclerosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2010</year>) <volume>30</volume>(<issue>5</issue>):<fpage>892</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.110.204545</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonasson</surname> <given-names>L</given-names></name> <name><surname>Holm</surname> <given-names>J</given-names></name> <name><surname>Skalli</surname> <given-names>O</given-names></name> <name><surname>Bondjers</surname> <given-names>G</given-names></name> <name><surname>Hansson</surname> <given-names>GK</given-names></name></person-group>. <article-title>Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque</article-title>. <source>Arteriosclerosis</source> (<year>1986</year>) <volume>6</volume>(<issue>2</issue>):<fpage>131</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.6.2.131</pub-id><pub-id pub-id-type="pmid">2937395</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Immunity, atherosclerosis and cardiovascular disease</article-title>. <source>BMC Med</source> (<year>2013</year>) <volume>11</volume>(<issue>1</issue>):<fpage>117</fpage>.<pub-id pub-id-type="doi">10.1186/1741-7015-11-117</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lichtman</surname> <given-names>AH</given-names></name> <name><surname>Binder</surname> <given-names>CJ</given-names></name> <name><surname>Tsimikas</surname> <given-names>S</given-names></name> <name><surname>Witztum</surname> <given-names>JL</given-names></name></person-group>. <article-title>Adaptive immunity in atherogenesis: new insights and therapeutic approaches</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1172/JCI63108</pub-id><pub-id pub-id-type="pmid">23281407</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Q</given-names></name> <name><surname>Dietrich</surname> <given-names>H</given-names></name> <name><surname>Steiner</surname> <given-names>HJ</given-names></name> <name><surname>Gown</surname> <given-names>AM</given-names></name> <name><surname>Schoel</surname> <given-names>B</given-names></name> <name><surname>Mikuz</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65</article-title>. <source>Arterioscler Thromb</source> (<year>1992</year>) <volume>12</volume>(<issue>7</issue>):<fpage>789</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.12.7.789</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palinski</surname> <given-names>W</given-names></name> <name><surname>Miller</surname> <given-names>E</given-names></name> <name><surname>Witztum</surname> <given-names>JL</given-names></name></person-group>. <article-title>Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1995</year>) <volume>92</volume>(<issue>3</issue>):<fpage>821</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.92.3.821</pub-id><pub-id pub-id-type="pmid">7846059</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virella</surname> <given-names>G</given-names></name> <name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name></person-group>. <article-title>Humoral immunity and atherosclerosis</article-title>. <source>Nat Med</source> (<year>2003</year>) <volume>9</volume>(<issue>3</issue>):<fpage>243</fpage>&#x02013;<lpage>4</lpage> author reply 244&#x02013;245,<pub-id pub-id-type="doi">10.1038/nm0303-243</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maganto-Garcia</surname> <given-names>E</given-names></name> <name><surname>Tarrio</surname> <given-names>M</given-names></name> <name><surname>Lichtman</surname> <given-names>AH</given-names></name></person-group>. <article-title>Mouse models of atherosclerosis</article-title>. <source>Curr Protoc Immunol</source> (<year>2012</year>) <volume>15</volume>:<fpage>1</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1002/0471142735.im1524s96</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matoba</surname> <given-names>T</given-names></name> <name><surname>Sato</surname> <given-names>K</given-names></name> <name><surname>Egashira</surname> <given-names>K</given-names></name></person-group>. <article-title>Mouse models of plaque rupture</article-title>. <source>Curr Opin Lipidol</source> (<year>2013</year>) <volume>24</volume>(<issue>5</issue>):<fpage>419</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1097/MOL.0b013e3283646e4d</pub-id><pub-id pub-id-type="pmid">23942269</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname> <given-names>J</given-names></name> <name><surname>Harats</surname> <given-names>D</given-names></name> <name><surname>Gilburd</surname> <given-names>B</given-names></name> <name><surname>Afek</surname> <given-names>A</given-names></name> <name><surname>Shaish</surname> <given-names>A</given-names></name> <name><surname>Kopolovic</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice</article-title>. <source>Circulation</source> (<year>2000</year>) <volume>102</volume>(<issue>15</issue>):<fpage>1822</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.102.15.1822</pub-id><pub-id pub-id-type="pmid">11023938</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>X</given-names></name> <name><surname>Robertson</surname> <given-names>AK</given-names></name> <name><surname>Hjerpe</surname> <given-names>C</given-names></name> <name><surname>Hansson</surname> <given-names>GK</given-names></name></person-group>. <article-title>Adoptive transfer of CD4&#x0002B; T cells reactive to modified low-density lipoprotein aggravates atherosclerosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2006</year>) <volume>26</volume>(<issue>4</issue>):<fpage>864</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.0000206122.61591.ff</pub-id><pub-id pub-id-type="pmid">16456097</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ait-Oufella</surname> <given-names>H</given-names></name> <name><surname>Salomon</surname> <given-names>BL</given-names></name> <name><surname>Potteaux</surname> <given-names>S</given-names></name> <name><surname>Robertson</surname> <given-names>AK</given-names></name> <name><surname>Gourdy</surname> <given-names>P</given-names></name> <name><surname>Zoll</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Natural regulatory T cells control the development of atherosclerosis in mice</article-title>. <source>Nat Med</source> (<year>2006</year>) <volume>12</volume>(<issue>2</issue>):<fpage>178</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1038/nm1343</pub-id><pub-id pub-id-type="pmid">16462800</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tupin</surname> <given-names>E</given-names></name> <name><surname>Nicoletti</surname> <given-names>A</given-names></name> <name><surname>Elhage</surname> <given-names>R</given-names></name> <name><surname>Rudling</surname> <given-names>M</given-names></name> <name><surname>Ljunggren</surname> <given-names>HG</given-names></name> <name><surname>Hansson</surname> <given-names>GK</given-names></name> <etal/></person-group> <article-title>CD1d-dependent activation of NKT cells aggravates atherosclerosis</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>199</volume>(<issue>3</issue>):<fpage>417</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20030997</pub-id><pub-id pub-id-type="pmid">14744994</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>X</given-names></name> <name><surname>Yu</surname> <given-names>X</given-names></name> <name><surname>Ding</surname> <given-names>YJ</given-names></name> <name><surname>Fu</surname> <given-names>QQ</given-names></name> <name><surname>Xie</surname> <given-names>JJ</given-names></name> <name><surname>Tang</surname> <given-names>TT</given-names></name> <etal/></person-group> <article-title>The Th17/Treg imbalance in patients with acute coronary syndrome</article-title>. <source>Clin Immunol</source> (<year>2008</year>) <volume>127</volume>(<issue>1</issue>):<fpage>89</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2008.01.009</pub-id><pub-id pub-id-type="pmid">18294918</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Q</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <name><surname>Chen</surname> <given-names>K</given-names></name> <name><surname>Zhou</surname> <given-names>Q</given-names></name> <name><surname>Wei</surname> <given-names>W</given-names></name></person-group>. <article-title>The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2010</year>) <volume>394</volume>(<issue>3</issue>):<fpage>836</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2010.03.090</pub-id><pub-id pub-id-type="pmid">20302843</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gistera</surname> <given-names>A</given-names></name> <name><surname>Robertson</surname> <given-names>AK</given-names></name> <name><surname>Andersson</surname> <given-names>J</given-names></name> <name><surname>Ketelhuth</surname> <given-names>DF</given-names></name> <name><surname>Ovchinnikova</surname> <given-names>O</given-names></name> <name><surname>Nilsson</surname> <given-names>SK</given-names></name> <etal/></person-group> <article-title>Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway</article-title>. <source>Sci Transl Med</source> (<year>2013</year>) <volume>5</volume>(<issue>196</issue>):<fpage>196ra100</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3006133</pub-id><pub-id pub-id-type="pmid">23903754</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giubilato</surname> <given-names>S</given-names></name> <name><surname>Liuzzo</surname> <given-names>G</given-names></name> <name><surname>Brugaletta</surname> <given-names>S</given-names></name> <name><surname>Pitocco</surname> <given-names>D</given-names></name> <name><surname>Graziani</surname> <given-names>F</given-names></name> <name><surname>Smaldone</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Expansion of CD4&#x0002B;CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus</article-title>. <source>Eur Heart J</source> (<year>2011</year>) <volume>32</volume>(<issue>10</issue>):<fpage>1214</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1093/eurheartj/ehq499</pub-id><pub-id pub-id-type="pmid">21217142</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname> <given-names>JE</given-names></name> <name><surname>Feig</surname> <given-names>JL</given-names></name></person-group>. <article-title>Macrophages, dendritic cells, and regression of atherosclerosis</article-title>. <source>Front Physiol</source> (<year>2012</year>) <volume>3</volume>:<fpage>286</fpage>.<pub-id pub-id-type="doi">10.3389/fphys.2012.00286</pub-id><pub-id pub-id-type="pmid">22934038</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Millonig</surname> <given-names>G</given-names></name> <name><surname>Niederegger</surname> <given-names>H</given-names></name> <name><surname>Rabl</surname> <given-names>W</given-names></name> <name><surname>Hochleitner</surname> <given-names>BW</given-names></name> <name><surname>Hoefer</surname> <given-names>D</given-names></name> <name><surname>Romani</surname> <given-names>N</given-names></name> <etal/></person-group> <article-title>Network of vascular-associated dendritic cells in intima of healthy young individuals</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2001</year>) <volume>21</volume>(<issue>4</issue>):<fpage>503</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.21.4.503</pub-id><pub-id pub-id-type="pmid">11304464</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname> <given-names>A</given-names></name> <name><surname>Lochno</surname> <given-names>M</given-names></name> <name><surname>Traeg</surname> <given-names>F</given-names></name> <name><surname>Cicha</surname> <given-names>I</given-names></name> <name><surname>Reiss</surname> <given-names>C</given-names></name> <name><surname>Stumpf</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques</article-title>. <source>Atherosclerosis</source> (<year>2004</year>) <volume>176</volume>(<issue>1</issue>):<fpage>101</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.04.027</pub-id><pub-id pub-id-type="pmid">15306181</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>P</given-names></name> <name><surname>Yu</surname> <given-names>YR</given-names></name> <name><surname>Spencer</surname> <given-names>JA</given-names></name> <name><surname>Johnson</surname> <given-names>AE</given-names></name> <name><surname>Vallanat</surname> <given-names>CT</given-names></name> <name><surname>Fong</surname> <given-names>AM</given-names></name> <etal/></person-group> <article-title>CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2008</year>) <volume>28</volume>(<issue>2</issue>):<fpage>243</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.107.158675</pub-id><pub-id pub-id-type="pmid">18079406</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bobryshev</surname> <given-names>YV</given-names></name> <name><surname>Watanabe</surname> <given-names>T</given-names></name></person-group>. <article-title>Ultrastructural evidence for association of vascular dendritic cells with T-lymphocytes and with B-cells in human atherosclerosis</article-title>. <source>J Submicrosc Cytol Pathol</source> (<year>1997</year>) <volume>29</volume>(<issue>2</issue>):<fpage>209</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">9165715</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woollard</surname> <given-names>KJ</given-names></name> <name><surname>Geissmann</surname> <given-names>F</given-names></name></person-group>. <article-title>Monocytes in atherosclerosis: subsets and functions</article-title>. <source>Nat Rev Cardiol</source> (<year>2010</year>) <volume>7</volume>(<issue>2</issue>):<fpage>77</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1038/nrcardio.2009.228</pub-id><pub-id pub-id-type="pmid">20065951</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leitinger</surname> <given-names>N</given-names></name> <name><surname>Schulman</surname> <given-names>IG</given-names></name></person-group>. <article-title>Phenotypic polarization of macrophages in atherosclerosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2013</year>) <volume>33</volume>(<issue>6</issue>):<fpage>1120</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300173</pub-id><pub-id pub-id-type="pmid">23640492</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovanen</surname> <given-names>PT</given-names></name></person-group>. <article-title>Mast cells: multipotent local effector cells in atherothrombosis</article-title>. <source>Immunol Rev</source> (<year>2007</year>) <volume>217</volume>:<fpage>105</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2007.00515.x</pub-id><pub-id pub-id-type="pmid">17498055</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname> <given-names>S</given-names></name> <name><surname>Vink</surname> <given-names>A</given-names></name> <name><surname>Bot</surname> <given-names>I</given-names></name> <name><surname>Quax</surname> <given-names>PH</given-names></name> <name><surname>de Borst</surname> <given-names>GJ</given-names></name> <name><surname>de Vries</surname> <given-names>JP</given-names></name> <etal/></person-group> <article-title>Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events</article-title>. <source>Eur Heart J</source> (<year>2013</year>). [Epub ahead of print].<pub-id pub-id-type="doi">10.1093/eurheartj/eht186</pub-id><pub-id pub-id-type="pmid">23756333</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname> <given-names>GZ</given-names></name> <name><surname>Huang</surname> <given-names>YH</given-names></name> <name><surname>Swedenborg</surname> <given-names>J</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism</article-title>. <source>Atherosclerosis</source> (<year>2003</year>) <volume>169</volume>(<issue>1</issue>):<fpage>77</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/S0021-9150(03)00146-1</pub-id><pub-id pub-id-type="pmid">12860253</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Giscombe</surname> <given-names>R</given-names></name> <name><surname>Holm</surname> <given-names>G</given-names></name> <name><surname>Lefvert</surname> <given-names>AK</given-names></name> <name><surname>Nilsson</surname> <given-names>J</given-names></name></person-group>. <article-title>Induction of T-cell activation by oxidized low density lipoprotein</article-title>. <source>Arterioscler Thromb</source> (<year>1992</year>) <volume>12</volume>(<issue>4</issue>):<fpage>461</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.12.4.461</pub-id><pub-id pub-id-type="pmid">1558837</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease</article-title>. <source>Clin Immunol</source> (<year>2010</year>) <volume>134</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2009.08.013</pub-id><pub-id pub-id-type="pmid">19748321</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name> <name><surname>Virella</surname> <given-names>G</given-names></name> <name><surname>Orchard</surname> <given-names>TJ</given-names></name> <name><surname>Koskinen</surname> <given-names>S</given-names></name> <name><surname>Evans</surname> <given-names>RW</given-names></name> <name><surname>Becker</surname> <given-names>DJ</given-names></name> <etal/></person-group> <article-title>Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus</article-title>. <source>Clin Immunol</source> (<year>1999</year>) <volume>90</volume>(<issue>2</issue>):<fpage>165</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1006/clim.1998.4631</pub-id><pub-id pub-id-type="pmid">10080827</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Camejo</surname> <given-names>G</given-names></name> <name><surname>Lalaguna</surname> <given-names>F</given-names></name> <name><surname>Lopez</surname> <given-names>F</given-names></name> <name><surname>Starosta</surname> <given-names>R</given-names></name></person-group>. <article-title>Characterization and properties of a lipoprotein-complexing proteoglycan from human aorta</article-title>. <source>Atherosclerosis</source> (<year>1980</year>) <volume>35</volume>(<issue>3</issue>):<fpage>307</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/0021-9150(80)90129-X</pub-id><pub-id pub-id-type="pmid">7362702</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tabas</surname> <given-names>I</given-names></name> <name><surname>Williams</surname> <given-names>KJ</given-names></name> <name><surname>Boren</surname> <given-names>J</given-names></name></person-group>. <article-title>Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications</article-title>. <source>Circulation</source> (<year>2007</year>) <volume>116</volume>(<issue>16</issue>):<fpage>1832</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.676890</pub-id></citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Nilsson</surname> <given-names>J</given-names></name> <name><surname>Haegerstrand</surname> <given-names>A</given-names></name> <name><surname>Hamsten</surname> <given-names>A</given-names></name> <name><surname>Wigzell</surname> <given-names>H</given-names></name> <name><surname>Gidlund</surname> <given-names>M</given-names></name></person-group>. <article-title>Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1990</year>) <volume>87</volume>(<issue>3</issue>):<fpage>904</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.87.3.904</pub-id><pub-id pub-id-type="pmid">2300583</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berliner</surname> <given-names>JA</given-names></name> <name><surname>Territo</surname> <given-names>MC</given-names></name> <name><surname>Sevanian</surname> <given-names>A</given-names></name> <name><surname>Ramin</surname> <given-names>S</given-names></name> <name><surname>Kim</surname> <given-names>JA</given-names></name> <name><surname>Bamshad</surname> <given-names>B</given-names></name> <etal/></person-group> <article-title>Minimally modified low density lipoprotein stimulates monocyte endothelial interactions</article-title>. <source>J Clin Invest</source> (<year>1990</year>) <volume>85</volume>(<issue>4</issue>):<fpage>1260</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1172/JCI114562</pub-id><pub-id pub-id-type="pmid">2318980</pub-id></citation></ref>
<ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elinder</surname> <given-names>LS</given-names></name> <name><surname>Dumitrescu</surname> <given-names>A</given-names></name> <name><surname>Larsson</surname> <given-names>P</given-names></name> <name><surname>Hedin</surname> <given-names>U</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Claesson</surname> <given-names>HE</given-names></name></person-group>. <article-title>Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>1997</year>) <volume>17</volume>(<issue>10</issue>):<fpage>2257</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.17.10.2257</pub-id><pub-id pub-id-type="pmid">9351398</pub-id></citation></ref>
<ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atout</surname> <given-names>R</given-names></name> <name><surname>Karabina</surname> <given-names>SA</given-names></name> <name><surname>Dollet</surname> <given-names>S</given-names></name> <name><surname>Carreras</surname> <given-names>M</given-names></name> <name><surname>Payre</surname> <given-names>C</given-names></name> <name><surname>Andre</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>Human group X secreted phospholipase A2 induces dendritic cell maturation through lipoprotein-dependent and -independent mechanisms</article-title>. <source>Atherosclerosis</source> (<year>2012</year>) <volume>222</volume>(<issue>2</issue>):<fpage>367</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.03.014</pub-id><pub-id pub-id-type="pmid">22494626</pub-id></citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>YH</given-names></name> <name><surname>Schafer-Elinder</surname> <given-names>L</given-names></name> <name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Claesson</surname> <given-names>HE</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism</article-title>. <source>Clin Exp Immunol</source> (<year>1999</year>) <volume>116</volume>(<issue>2</issue>):<fpage>326</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2249.1999.00871.x</pub-id><pub-id pub-id-type="pmid">10337026</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname> <given-names>I</given-names></name> <name><surname>Edsfeldt</surname> <given-names>A</given-names></name> <name><surname>Ko</surname> <given-names>NY</given-names></name> <name><surname>Grufman</surname> <given-names>H</given-names></name> <name><surname>Berg</surname> <given-names>K</given-names></name> <name><surname>Bjorkbacka</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2012</year>) <volume>32</volume>(<issue>6</issue>):<fpage>1505</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.112.249854</pub-id><pub-id pub-id-type="pmid">22499993</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Huang</surname> <given-names>YH</given-names></name> <name><surname>Ronnelid</surname> <given-names>J</given-names></name> <name><surname>Schafer-Elinder</surname> <given-names>L</given-names></name></person-group>. <article-title>Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>1997</year>) <volume>17</volume>(<issue>5</issue>):<fpage>963</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.17.5.963</pub-id><pub-id pub-id-type="pmid">9157962</pub-id></citation></ref>
<ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname> <given-names>AD</given-names></name> <name><surname>Leitinger</surname> <given-names>N</given-names></name> <name><surname>Navab</surname> <given-names>M</given-names></name> <name><surname>Faull</surname> <given-names>KF</given-names></name> <name><surname>Horkko</surname> <given-names>S</given-names></name> <name><surname>Witztum</surname> <given-names>JL</given-names></name> <etal/></person-group> <article-title>Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo</article-title>. <source>J Biol Chem</source> (<year>1997</year>) <volume>272</volume>(<issue>21</issue>):<fpage>13597</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.272.21.13597</pub-id><pub-id pub-id-type="pmid">9153208</pub-id></citation></ref>
<ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname> <given-names>FH</given-names></name> <name><surname>Kennedy</surname> <given-names>S</given-names></name> <name><surname>Spickett</surname> <given-names>CM</given-names></name></person-group>. <article-title>Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation</article-title>. <source>Free Radic Biol Med</source> (<year>2012</year>) <volume>52</volume>(<issue>2</issue>):<fpage>266</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.10.481</pub-id><pub-id pub-id-type="pmid">22080084</pub-id></citation></ref>
<ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>YI</given-names></name> <name><surname>Choi</surname> <given-names>SH</given-names></name> <name><surname>Wiesner</surname> <given-names>P</given-names></name> <name><surname>Fang</surname> <given-names>L</given-names></name> <name><surname>Harkewicz</surname> <given-names>R</given-names></name> <name><surname>Hartvigsen</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity</article-title>. <source>Circ Res</source> (<year>2011</year>) <volume>108</volume>(<issue>2</issue>):<fpage>235</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.223875</pub-id></citation></ref>
<ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birukov</surname> <given-names>KG</given-names></name></person-group>. <article-title>Oxidized lipids: the two faces of vascular inflammation</article-title>. <source>Curr Atheroscler Rep</source> (<year>2006</year>) <volume>8</volume>(<issue>3</issue>):<fpage>223</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1007/s11883-006-0077-x</pub-id><pub-id pub-id-type="pmid">16640959</pub-id></citation></ref>
<ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname> <given-names>ME</given-names></name> <name><surname>Li</surname> <given-names>XM</given-names></name> <name><surname>Gugiu</surname> <given-names>BG</given-names></name> <name><surname>Gu</surname> <given-names>X</given-names></name> <name><surname>Qin</surname> <given-names>J</given-names></name> <name><surname>Salomon</surname> <given-names>RG</given-names></name> <etal/></person-group> <article-title>The lipid whisker model of the structure of oxidized cell membranes</article-title>. <source>J Biol Chem</source> (<year>2008</year>) <volume>283</volume>(<issue>4</issue>):<fpage>2385</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M707348200</pub-id><pub-id pub-id-type="pmid">18045864</pub-id></citation></ref>
<ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bochkov</surname> <given-names>VN</given-names></name> <name><surname>Oskolkova</surname> <given-names>OV</given-names></name> <name><surname>Birukov</surname> <given-names>KG</given-names></name> <name><surname>Levonen</surname> <given-names>AL</given-names></name> <name><surname>Binder</surname> <given-names>CJ</given-names></name> <name><surname>Stockl</surname> <given-names>J</given-names></name></person-group>. <article-title>Generation and biological activities of oxidized phospholipids</article-title>. <source>Antioxid Redox Signal</source> (<year>2010</year>) <volume>12</volume>(<issue>8</issue>):<fpage>1009</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="doi">10.1089/ars.2009.2597</pub-id><pub-id pub-id-type="pmid">19686040</pub-id></citation></ref>
<ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitan</surname> <given-names>I</given-names></name> <name><surname>Volkov</surname> <given-names>S</given-names></name> <name><surname>Subbaiah</surname> <given-names>PV</given-names></name></person-group>. <article-title>Oxidized LDL: diversity, patterns of recognition, and pathophysiology</article-title>. <source>Antioxid Redox Signal</source> (<year>2010</year>) <volume>13</volume>(<issue>1</issue>):<fpage>39</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1089/ars.2009.2733</pub-id><pub-id pub-id-type="pmid">19888833</pub-id></citation></ref>
<ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname> <given-names>RG</given-names></name></person-group>. <article-title>Structural identification and cardiovascular activities of oxidized phospholipids</article-title>. <source>Circ Res</source> (<year>2012</year>) <volume>111</volume>(<issue>7</issue>):<fpage>930</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.275388</pub-id></citation></ref>
<ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weismann</surname> <given-names>D</given-names></name> <name><surname>Binder</surname> <given-names>CJ</given-names></name></person-group>. <article-title>The innate immune response to products of phospholipid peroxidation</article-title>. <source>Biochim Biophys Acta</source> (<year>2012</year>) <volume>1818</volume>(<issue>10</issue>):<fpage>2465</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbamem.2012.01.018</pub-id><pub-id pub-id-type="pmid">22305963</pub-id></citation></ref>
<ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname> <given-names>A</given-names></name> <name><surname>Fredrikson</surname> <given-names>GN</given-names></name> <name><surname>Schiopu</surname> <given-names>A</given-names></name> <name><surname>Ljungcrantz</surname> <given-names>I</given-names></name> <name><surname>Soderberg</surname> <given-names>I</given-names></name> <name><surname>Jansson</surname> <given-names>B</given-names></name> <etal/></person-group> <article-title>Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100</article-title>. <source>Atherosclerosis</source> (<year>2007</year>) <volume>190</volume>(<issue>2</issue>):<fpage>298</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.03.032</pub-id><pub-id pub-id-type="pmid">16677655</pub-id></citation></ref>
<ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jialal</surname> <given-names>I</given-names></name> <name><surname>Devaraj</surname> <given-names>S</given-names></name> <name><surname>Adams-Huet</surname> <given-names>B</given-names></name> <name><surname>Chen</surname> <given-names>X</given-names></name> <name><surname>Kaur</surname> <given-names>H</given-names></name></person-group>. <article-title>Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2012</year>) <volume>97</volume>(<issue>10</issue>):<fpage>E1844</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1210/jc.2012-2498</pub-id><pub-id pub-id-type="pmid">22872691</pub-id></citation></ref>
<ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Lemne</surname> <given-names>C</given-names></name> <name><surname>Thulin</surname> <given-names>T</given-names></name> <name><surname>Witztum</surname> <given-names>JL</given-names></name> <name><surname>de Faire</surname> <given-names>U</given-names></name></person-group>. <article-title>Circulating oxidized low-density lipoprotein is increased in hypertension</article-title>. <source>Clin Sci (Lond)</source> (<year>2003</year>) <volume>105</volume>(<issue>5</issue>):<fpage>615</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1042/CS20030152</pub-id><pub-id pub-id-type="pmid">12837127</pub-id></citation></ref>
<ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoogeveen</surname> <given-names>RC</given-names></name> <name><surname>Ballantyne</surname> <given-names>CM</given-names></name> <name><surname>Bang</surname> <given-names>H</given-names></name> <name><surname>Heiss</surname> <given-names>G</given-names></name> <name><surname>Duncan</surname> <given-names>BB</given-names></name> <name><surname>Folsom</surname> <given-names>AR</given-names></name> <etal/></person-group> <article-title>Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study</article-title>. <source>Diabetologia</source> (<year>2007</year>) <volume>50</volume>(<issue>1</issue>):<fpage>36</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-006-0533-8</pub-id><pub-id pub-id-type="pmid">17136392</pub-id></citation></ref>
<ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name> <name><surname>Hunt</surname> <given-names>KJ</given-names></name> <name><surname>Baker</surname> <given-names>NL</given-names></name> <name><surname>Virella</surname> <given-names>G</given-names></name> <name><surname>Moritz</surname> <given-names>T</given-names></name></person-group>. <article-title>The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study</article-title>. <source>Atherosclerosis</source> (<year>2012</year>) <volume>224</volume>(<issue>2</issue>):<fpage>526</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.08.006</pub-id><pub-id pub-id-type="pmid">22963984</pub-id></citation></ref>
<ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname> <given-names>S</given-names></name> <name><surname>Hawken</surname> <given-names>S</given-names></name> <name><surname>Ounpuu</surname> <given-names>S</given-names></name> <name><surname>Dans</surname> <given-names>T</given-names></name> <name><surname>Avezum</surname> <given-names>A</given-names></name> <name><surname>Lanas</surname> <given-names>F</given-names></name> <etal/></person-group> <article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</article-title>. <source>Lancet</source> (<year>2004</year>) <volume>364</volume>(<issue>9438</issue>):<fpage>937</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(04)17018-9</pub-id><pub-id pub-id-type="pmid">15364185</pub-id></citation></ref>
<ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yanbaeva</surname> <given-names>DG</given-names></name> <name><surname>Dentener</surname> <given-names>MA</given-names></name> <name><surname>Creutzberg</surname> <given-names>EC</given-names></name> <name><surname>Wesseling</surname> <given-names>G</given-names></name> <name><surname>Wouters</surname> <given-names>EF</given-names></name></person-group>. <article-title>Systemic effects of smoking</article-title>. <source>Chest</source> (<year>2007</year>) <volume>131</volume>(<issue>5</issue>):<fpage>1557</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1378/chest.06-2179</pub-id></citation></ref>
<ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penn</surname> <given-names>A</given-names></name> <name><surname>Snyder</surname> <given-names>CA</given-names></name></person-group>. <article-title>Inhalation of sidestream cigarette smoke accelerates development of arteriosclerotic plaques</article-title>. <source>Circulation</source> (<year>1993</year>) <volume>88</volume>(<issue>4 Pt 1</issue>):<fpage>1820</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.88.4.1820</pub-id><pub-id pub-id-type="pmid">8403327</pub-id></citation></ref>
<ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>BQ</given-names></name> <name><surname>Sun</surname> <given-names>YP</given-names></name> <name><surname>Sievers</surname> <given-names>RE</given-names></name> <name><surname>Isenberg</surname> <given-names>WM</given-names></name> <name><surname>Glantz</surname> <given-names>SA</given-names></name> <name><surname>Parmley</surname> <given-names>WW</given-names></name></person-group>. <article-title>Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits</article-title>. <source>J Am Coll Cardiol</source> (<year>1993</year>) <volume>21</volume>(<issue>1</issue>):<fpage>225</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/0735-1097(93)90741-I</pub-id><pub-id pub-id-type="pmid">8417066</pub-id></citation></ref>
<ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gairola</surname> <given-names>CG</given-names></name> <name><surname>Drawdy</surname> <given-names>ML</given-names></name> <name><surname>Block</surname> <given-names>AE</given-names></name> <name><surname>Daugherty</surname> <given-names>A</given-names></name></person-group>. <article-title>Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E<sup>-/-</sup> mice</article-title>. <source>Atherosclerosis</source> (<year>2001</year>) <volume>156</volume>(<issue>1</issue>):<fpage>49</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1016/S0021-9150(00)00621-3</pub-id><pub-id pub-id-type="pmid">11368996</pub-id></citation></ref>
<ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname> <given-names>JD</given-names></name> <name><surname>Frei</surname> <given-names>B</given-names></name> <name><surname>Longmire</surname> <given-names>AW</given-names></name> <name><surname>Gaziano</surname> <given-names>JM</given-names></name> <name><surname>Lynch</surname> <given-names>SM</given-names></name> <name><surname>Shyr</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage</article-title>. <source>N Engl J Med</source> (<year>1995</year>) <volume>332</volume>(<issue>18</issue>):<fpage>1198</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="doi">10.1056/NEJM199505043321804</pub-id><pub-id pub-id-type="pmid">7700313</pub-id></citation></ref>
<ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunitomo</surname> <given-names>M</given-names></name> <name><surname>Yamaguchi</surname> <given-names>Y</given-names></name> <name><surname>Kagota</surname> <given-names>S</given-names></name> <name><surname>Yoshikawa</surname> <given-names>N</given-names></name> <name><surname>Nakamura</surname> <given-names>K</given-names></name> <name><surname>Shinozuka</surname> <given-names>K</given-names></name></person-group>. <article-title>Biochemical evidence of atherosclerosis progression mediated by increased oxidative stress in apolipoprotein E-deficient spontaneously hyperlipidemic mice exposed to chronic cigarette smoke</article-title>. <source>J Pharmacol Sci</source> (<year>2009</year>) <volume>110</volume>(<issue>3</issue>):<fpage>354</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1254/jphs.09100FP</pub-id><pub-id pub-id-type="pmid">19571461</pub-id></citation></ref>
<ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname> <given-names>A</given-names></name> <name><surname>Bossios</surname> <given-names>A</given-names></name> <name><surname>Malmhall</surname> <given-names>C</given-names></name> <name><surname>Sjostrand</surname> <given-names>M</given-names></name> <name><surname>Eldh</surname> <given-names>M</given-names></name> <name><surname>Eldh</surname> <given-names>BM</given-names></name> <etal/></person-group> <article-title>Effects of tobacco smoke on IL-16 in CD8&#x0002B; cells from human airways and blood: a key role for oxygen free radicals?</article-title> <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2011</year>) <volume>300</volume>(<issue>1</issue>):<fpage>L43</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1152/ajplung.00387.2009</pub-id><pub-id pub-id-type="pmid">21036918</pub-id></citation></ref>
<ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname> <given-names>JA</given-names></name> <name><surname>Goldfine</surname> <given-names>AB</given-names></name> <name><surname>Gordon</surname> <given-names>MB</given-names></name> <name><surname>Creager</surname> <given-names>MA</given-names></name></person-group>. <article-title>Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans</article-title>. <source>Circulation</source> (<year>2001</year>) <volume>103</volume>(<issue>12</issue>):<fpage>1618</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.103.12.1618</pub-id><pub-id pub-id-type="pmid">11273987</pub-id></citation></ref>
<ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname> <given-names>T</given-names></name> <name><surname>Edelstein</surname> <given-names>D</given-names></name> <name><surname>Du</surname> <given-names>XL</given-names></name> <name><surname>Yamagishi</surname> <given-names>S</given-names></name> <name><surname>Matsumura</surname> <given-names>T</given-names></name> <name><surname>Kaneda</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage</article-title>. <source>Nature</source> (<year>2000</year>) <volume>404</volume>(<issue>6779</issue>):<fpage>787</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1038/35008121</pub-id><pub-id pub-id-type="pmid">10783895</pub-id></citation></ref>
<ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laursen</surname> <given-names>JB</given-names></name> <name><surname>Somers</surname> <given-names>M</given-names></name> <name><surname>Kurz</surname> <given-names>S</given-names></name> <name><surname>McCann</surname> <given-names>L</given-names></name> <name><surname>Warnholtz</surname> <given-names>A</given-names></name> <name><surname>Freeman</surname> <given-names>BA</given-names></name> <etal/></person-group> <article-title>Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin</article-title>. <source>Circulation</source> (<year>2001</year>) <volume>103</volume>(<issue>9</issue>):<fpage>1282</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.103.9.1282</pub-id><pub-id pub-id-type="pmid">11238274</pub-id></citation></ref>
<ref id="B86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>CC</given-names></name> <name><surname>Reusch</surname> <given-names>JE</given-names></name></person-group>. <article-title>Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival</article-title>. <source>Am J Cardiol</source> (<year>2012</year>) <volume>110</volume>(<issue>9 Suppl</issue>):<fpage>58B</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2012.08.036</pub-id><pub-id pub-id-type="pmid">23062569</pub-id></citation></ref>
<ref id="B87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shirwany</surname> <given-names>NA</given-names></name> <name><surname>Zou</surname> <given-names>MH</given-names></name></person-group>. <article-title>Vascular inflammation is a missing link for diabetes-enhanced atherosclerotic cardiovascular diseases</article-title>. <source>Front Biosci</source> (<year>2012</year>) <volume>17</volume>:<fpage>1140</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.2741/3978</pub-id><pub-id pub-id-type="pmid">22201795</pub-id></citation></ref>
<ref id="B88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>SF</given-names></name> <name><surname>Ramasamy</surname> <given-names>R</given-names></name> <name><surname>Schmidt</surname> <given-names>AM</given-names></name></person-group>. <article-title>The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease</article-title>. <source>Expert Rev Mol Med</source> (<year>2009</year>) <volume>11</volume>:<fpage>e9</fpage>.<pub-id pub-id-type="doi">10.1017/S146239940900101X</pub-id><pub-id pub-id-type="pmid">19278572</pub-id></citation></ref>
<ref id="B89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>L</given-names></name> <name><surname>Raman</surname> <given-names>KG</given-names></name> <name><surname>Lee</surname> <given-names>KJ</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Ferran</surname> <given-names>LJ</given-names> <suffix>Jr</suffix></name> <name><surname>Chow</surname> <given-names>WS</given-names></name> <etal/></person-group> <article-title>Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts</article-title>. <source>Nat Med</source> (<year>1998</year>) <volume>4</volume>(<issue>9</issue>):<fpage>1025</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1038/2012</pub-id><pub-id pub-id-type="pmid">9734395</pub-id></citation></ref>
<ref id="B90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soran</surname> <given-names>H</given-names></name> <name><surname>Durrington</surname> <given-names>PN</given-names></name></person-group>. <article-title>Susceptibility of LDL and its subfractions to glycation</article-title>. <source>Curr Opin Lipidol</source> (<year>2011</year>) <volume>22</volume>(<issue>4</issue>):<fpage>254</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1097/MOL.0b013e328348a43f</pub-id><pub-id pub-id-type="pmid">21734572</pub-id></citation></ref>
<ref id="B91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virella</surname> <given-names>G</given-names></name> <name><surname>Thorpe</surname> <given-names>SR</given-names></name> <name><surname>Alderson</surname> <given-names>NL</given-names></name> <name><surname>Stephan</surname> <given-names>EM</given-names></name> <name><surname>Atchley</surname> <given-names>D</given-names></name> <name><surname>Wagner</surname> <given-names>F</given-names></name> <etal/></person-group> <article-title>Autoimmune response to advanced glycosylation end-products of human LDL</article-title>. <source>J Lipid Res</source> (<year>2003</year>) <volume>44</volume>(<issue>3</issue>):<fpage>487</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1194/jlr.M200370-JLR200</pub-id><pub-id pub-id-type="pmid">12562876</pub-id></citation></ref>
<ref id="B92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bucala</surname> <given-names>R</given-names></name> <name><surname>Makita</surname> <given-names>Z</given-names></name> <name><surname>Koschinsky</surname> <given-names>T</given-names></name> <name><surname>Cerami</surname> <given-names>A</given-names></name> <name><surname>Vlassara</surname> <given-names>H</given-names></name></person-group>. <article-title>Lipid advanced glycosylation: pathway for lipid oxidation in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1993</year>) <volume>90</volume>(<issue>14</issue>):<fpage>6434</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.90.14.6434</pub-id><pub-id pub-id-type="pmid">8341651</pub-id></citation></ref>
<ref id="B93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dimitriadis</surname> <given-names>E</given-names></name> <name><surname>Griffin</surname> <given-names>M</given-names></name> <name><surname>Owens</surname> <given-names>D</given-names></name> <name><surname>Johnson</surname> <given-names>A</given-names></name> <name><surname>Collins</surname> <given-names>P</given-names></name> <name><surname>Tomkin</surname> <given-names>GH</given-names></name></person-group>. <article-title>Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition</article-title>. <source>Diabetologia</source> (<year>1995</year>) <volume>38</volume>(<issue>11</issue>):<fpage>1300</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1007/BF00401762</pub-id><pub-id pub-id-type="pmid">8582539</pub-id></citation></ref>
<ref id="B94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname> <given-names>MH</given-names></name> <name><surname>Watts</surname> <given-names>GF</given-names></name> <name><surname>Umpleby</surname> <given-names>AM</given-names></name> <name><surname>Hennessy</surname> <given-names>TR</given-names></name> <name><surname>Naoumova</surname> <given-names>R</given-names></name> <name><surname>Slavin</surname> <given-names>BM</given-names></name> <etal/></person-group> <article-title>Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM</article-title>. <source>Diabetologia</source> (<year>1995</year>) <volume>38</volume>(<issue>8</issue>):<fpage>959</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1007/BF00400586</pub-id><pub-id pub-id-type="pmid">7589883</pub-id></citation></ref>
<ref id="B95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname> <given-names>S</given-names></name> <name><surname>Matsushita</surname> <given-names>H</given-names></name> <name><surname>Li</surname> <given-names>W</given-names></name> <name><surname>Glassford</surname> <given-names>AJ</given-names></name> <name><surname>Asagami</surname> <given-names>T</given-names></name> <name><surname>Lee</surname> <given-names>KH</given-names></name> <etal/></person-group> <article-title>Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress</article-title>. <source>Circ Res</source> (<year>2001</year>) <volume>88</volume>(<issue>12</issue>):<fpage>1291</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/hh1201.092042</pub-id><pub-id pub-id-type="pmid">11420306</pub-id></citation></ref>
<ref id="B96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vinik</surname> <given-names>AI</given-names></name> <name><surname>Erbas</surname> <given-names>T</given-names></name> <name><surname>Park</surname> <given-names>TS</given-names></name> <name><surname>Nolan</surname> <given-names>R</given-names></name> <name><surname>Pittenger</surname> <given-names>GL</given-names></name></person-group>. <article-title>Platelet dysfunction in type 2 diabetes</article-title>. <source>Diabetes Care</source> (<year>2001</year>) <volume>24</volume>(<issue>8</issue>):<fpage>1476</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.2337/diacare.24.8.1476</pub-id></citation></ref>
<ref id="B97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mironova</surname> <given-names>MA</given-names></name> <name><surname>Klein</surname> <given-names>RL</given-names></name> <name><surname>Virella</surname> <given-names>GT</given-names></name> <name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name></person-group>. <article-title>Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes</article-title>. <source>Diabetes</source> (<year>2000</year>) <volume>49</volume>(<issue>6</issue>):<fpage>1033</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.49.6.1033</pub-id><pub-id pub-id-type="pmid">10866057</pub-id></citation></ref>
<ref id="B98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mironova</surname> <given-names>M</given-names></name> <name><surname>Virella</surname> <given-names>G</given-names></name> <name><surname>Virella-Lowell</surname> <given-names>I</given-names></name> <name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name></person-group>. <article-title>Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls</article-title>. <source>Clin Immunol Immunopathol</source> (<year>1997</year>) <volume>85</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1006/clin.1997.4404</pub-id><pub-id pub-id-type="pmid">9325072</pub-id></citation></ref>
<ref id="B99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virella</surname> <given-names>G</given-names></name> <name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name></person-group>. <article-title>The pathogenic role of the adaptive immune response to modified LDL in diabetes</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2012</year>) <volume>3</volume>:<fpage>76</fpage>.<pub-id pub-id-type="doi">10.3389/fendo.2012.00076</pub-id><pub-id pub-id-type="pmid">22715334</pub-id></citation></ref>
<ref id="B100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname> <given-names>CJ</given-names></name></person-group>. <article-title>Naturally occurring IgM antibodies to oxidation-specific epitopes</article-title>. <source>Adv Exp Med Biol</source> (<year>2012</year>) <volume>750</volume>:<fpage>2</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1007/978-1-4614-3461-0_1</pub-id><pub-id pub-id-type="pmid">22903662</pub-id></citation></ref>
<ref id="B101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shoenfeld</surname> <given-names>Y</given-names></name> <name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Dearing</surname> <given-names>LD</given-names></name> <name><surname>Matsuura</surname> <given-names>E</given-names></name></person-group>. <article-title>Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?</article-title> <source>Circulation</source> (<year>2004</year>) <volume>110</volume>(<issue>17</issue>):<fpage>2552</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000143225.07377.EA</pub-id></citation></ref>
<ref id="B102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajeganova</surname> <given-names>S</given-names></name> <name><surname>Ehrnfelt</surname> <given-names>C</given-names></name> <name><surname>Alizadeh</surname> <given-names>R</given-names></name> <name><surname>Rohani</surname> <given-names>M</given-names></name> <name><surname>Jogestrand</surname> <given-names>T</given-names></name> <name><surname>Hafstrom</surname> <given-names>I</given-names></name> <etal/></person-group> <article-title>Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset &#x02013; a prospective cohort study</article-title>. <source>Rheumatology (Oxford)</source> (<year>2012</year>).<pub-id pub-id-type="doi">10.1093/rheumatology/ker204</pub-id><pub-id pub-id-type="pmid">21743088</pub-id></citation></ref>
<ref id="B103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anania</surname> <given-names>C</given-names></name> <name><surname>Gustafsson</surname> <given-names>T</given-names></name> <name><surname>Hua</surname> <given-names>X</given-names></name> <name><surname>Su</surname> <given-names>J</given-names></name> <name><surname>Vikstrom</surname> <given-names>M</given-names></name> <name><surname>de Faire</surname> <given-names>U</given-names></name> <etal/></person-group> <article-title>Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> (<year>2010</year>) <volume>12</volume>(<issue>6</issue>):<fpage>R214</fpage>.<pub-id pub-id-type="doi">10.1186/ar3193</pub-id><pub-id pub-id-type="pmid">21092251</pub-id></citation></ref>
<ref id="B104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caidahl</surname> <given-names>K</given-names></name> <name><surname>Hartford</surname> <given-names>M</given-names></name> <name><surname>Karlsson</surname> <given-names>T</given-names></name> <name><surname>Herlitz</surname> <given-names>J</given-names></name> <name><surname>Pettersson</surname> <given-names>K</given-names></name> <name><surname>de Faire</surname> <given-names>U</given-names></name> <etal/></person-group> <article-title>IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes</article-title>. <source>Int J Cardiol</source> (<year>2013</year>) <volume>167</volume>(<issue>2</issue>):<fpage>464</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijcard.2012.01.018</pub-id><pub-id pub-id-type="pmid">22305633</pub-id></citation></ref>
<ref id="B105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Faire</surname> <given-names>U</given-names></name> <name><surname>Su</surname> <given-names>J</given-names></name> <name><surname>Hua</surname> <given-names>X</given-names></name> <name><surname>Frostegard</surname> <given-names>A</given-names></name> <name><surname>Halldin</surname> <given-names>M</given-names></name> <name><surname>Hellenius</surname> <given-names>ML</given-names></name> <etal/></person-group> <article-title>Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism</article-title>. <source>J Autoimmun</source> (<year>2010</year>) <volume>34</volume>(<issue>2</issue>):<fpage>73</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2009.05.003</pub-id><pub-id pub-id-type="pmid">19726160</pub-id></citation></ref>
<ref id="B106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>J</given-names></name> <name><surname>Georgiades</surname> <given-names>A</given-names></name> <name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Thulin</surname> <given-names>T</given-names></name> <name><surname>de Faire</surname> <given-names>U</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension</article-title>. <source>Atherosclerosis</source> (<year>2006</year>) <volume>188</volume>(<issue>1</issue>):<fpage>160</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2005.10.017</pub-id><pub-id pub-id-type="pmid">16307748</pub-id></citation></ref>
<ref id="B107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>J</given-names></name> <name><surname>Hua</surname> <given-names>X</given-names></name> <name><surname>Concha</surname> <given-names>H</given-names></name> <name><surname>Svenungsson</surname> <given-names>E</given-names></name> <name><surname>Cederholm</surname> <given-names>A</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Natural antibodies against phosphorylcholine as potential protective factors in SLE</article-title>. <source>Rheumatology (Oxford)</source> (<year>2008</year>) <volume>47</volume>(<issue>8</issue>):<fpage>1144</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/ken120</pub-id><pub-id pub-id-type="pmid">18522961</pub-id></citation></ref>
<ref id="B108"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname> <given-names>CJ</given-names></name> <name><surname>Horkko</surname> <given-names>S</given-names></name> <name><surname>Dewan</surname> <given-names>A</given-names></name> <name><surname>Chang</surname> <given-names>MK</given-names></name> <name><surname>Kieu</surname> <given-names>EP</given-names></name> <name><surname>Goodyear</surname> <given-names>CS</given-names></name> <etal/></person-group> <article-title>Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL</article-title>. <source>Nat Med</source> (<year>2003</year>) <volume>9</volume>(<issue>6</issue>):<fpage>736</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1038/nm876</pub-id><pub-id pub-id-type="pmid">12740573</pub-id></citation></ref>
<ref id="B109"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faria-Neto</surname> <given-names>JR</given-names></name> <name><surname>Chyu</surname> <given-names>KY</given-names></name> <name><surname>Li</surname> <given-names>X</given-names></name> <name><surname>Dimayuga</surname> <given-names>PC</given-names></name> <name><surname>Ferreira</surname> <given-names>C</given-names></name> <name><surname>Yano</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice</article-title>. <source>Atherosclerosis</source> (<year>2006</year>) <volume>189</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2005.11.033</pub-id><pub-id pub-id-type="pmid">16386745</pub-id></citation></ref>
<ref id="B110"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caligiuri</surname> <given-names>G</given-names></name> <name><surname>Khallou-Laschet</surname> <given-names>J</given-names></name> <name><surname>Vandaele</surname> <given-names>M</given-names></name> <name><surname>Gaston</surname> <given-names>AT</given-names></name> <name><surname>Delignat</surname> <given-names>S</given-names></name> <name><surname>Mandet</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Phosphorylcholine-targeting immunization reduces atherosclerosis</article-title>. <source>J Am Coll Cardiol</source> (<year>2007</year>) <volume>50</volume>(<issue>6</issue>):<fpage>540</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.jacc.2006.11.054</pub-id><pub-id pub-id-type="pmid">17678738</pub-id></citation></ref>
<ref id="B111"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Faire</surname> <given-names>U</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Natural antibodies against phosphorylcholine in cardiovascular disease</article-title>. <source>Ann N Y Acad Sci</source> (<year>2009</year>) <volume>1173</volume>:<fpage>292</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04748.x</pub-id><pub-id pub-id-type="pmid">19758165</pub-id></citation></ref>
<ref id="B112"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiskesund</surname> <given-names>R</given-names></name> <name><surname>Su</surname> <given-names>J</given-names></name> <name><surname>Viksr&#x000F6;m</surname> <given-names>M</given-names></name> <name><surname>Faire</surname> <given-names>UD</given-names></name> <name><surname>Frosteg&#x000E5;rd</surname> <given-names>J</given-names></name></person-group>. <article-title>Phosphorylcholine antibodies of the Group I idiotype inhibit cell death and, at high levels, are strong protection markers for atherosclerosis development, particularly when combined with other antibodies against modified LDL</article-title>. <source>Results Immunol</source> (<year>2012</year>) <volume>2</volume>:<fpage>13</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1016/j.rinim.2012.01.001</pub-id></citation></ref>
<ref id="B113"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gronwall</surname> <given-names>C</given-names></name> <name><surname>Vas</surname> <given-names>J</given-names></name> <name><surname>Silverman</surname> <given-names>GJ</given-names></name></person-group>. <article-title>Protective roles of natural IgM antibodies</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>3</volume>:<fpage>66</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00066</pub-id></citation></ref>
<ref id="B114"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname> <given-names>Y</given-names></name> <name><surname>Poratkatz</surname> <given-names>BS</given-names></name> <name><surname>Gilburd</surname> <given-names>B</given-names></name> <name><surname>Barzilai</surname> <given-names>O</given-names></name> <name><surname>Ram</surname> <given-names>M</given-names></name> <name><surname>Blank</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults</article-title>. <source>Clin Rev Allergy Immunol</source> (<year>2012</year>) <volume>42</volume>(<issue>2</issue>):<fpage>154</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1007/s12016-010-8241-z</pub-id><pub-id pub-id-type="pmid">21229335</pub-id></citation></ref>
<ref id="B115"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agmon-Levin</surname> <given-names>N</given-names></name> <name><surname>Bat-sheva</surname> <given-names>PK</given-names></name> <name><surname>Barzilai</surname> <given-names>O</given-names></name> <name><surname>Ram</surname> <given-names>M</given-names></name> <name><surname>Lindeberg</surname> <given-names>S</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea</article-title>. <source>Ann N Y Acad Sci</source> (<year>2009</year>) <volume>1173</volume>:<fpage>675</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04671.x</pub-id><pub-id pub-id-type="pmid">19758215</pub-id></citation></ref>
<ref id="B116"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkan</surname> <given-names>AC</given-names></name> <name><surname>Sjoberg</surname> <given-names>B</given-names></name> <name><surname>Kolsrud</surname> <given-names>B</given-names></name> <name><surname>Ringertz</surname> <given-names>B</given-names></name> <name><surname>Hafstrom</surname> <given-names>I</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name></person-group>. <article-title>Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study</article-title>. <source>Arthritis Res Ther</source> (<year>2008</year>) <volume>10</volume>(<issue>2</issue>):<fpage>R34</fpage>.<pub-id pub-id-type="doi">10.1186/ar2388</pub-id><pub-id pub-id-type="pmid">18348715</pub-id></citation></ref>
<ref id="B117"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>I</given-names></name> <name><surname>Atout</surname> <given-names>R</given-names></name> <name><surname>Pedersen</surname> <given-names>NL</given-names></name> <name><surname>de Faire</surname> <given-names>U</given-names></name> <name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Ninio</surname> <given-names>E</given-names></name> <etal/></person-group> <article-title>Genetic and environmental regulation of inflammatory CVD biomarkers Lp-PLA2 and IgM anti-PC</article-title>. <source>Atherosclerosis</source> (<year>2011</year>) <volume>218</volume>(<issue>1</issue>):<fpage>117</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.04.038</pub-id><pub-id pub-id-type="pmid">21616491</pub-id></citation></ref>
<ref id="B118"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engelbertsen</surname> <given-names>D</given-names></name> <name><surname>Anand</surname> <given-names>DV</given-names></name> <name><surname>Fredrikson</surname> <given-names>GN</given-names></name> <name><surname>Hopkins</surname> <given-names>D</given-names></name> <name><surname>Corder</surname> <given-names>R</given-names></name> <name><surname>Shah</surname> <given-names>PK</given-names></name> <etal/></person-group> <article-title>High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes</article-title>. <source>J Intern Med</source> (<year>2012</year>) <volume>271</volume>(<issue>1</issue>):<fpage>82</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2796.2011.02411.x</pub-id><pub-id pub-id-type="pmid">21668821</pub-id></citation></ref>
<ref id="B119"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopes-Virella</surname> <given-names>MF</given-names></name> <name><surname>Virella</surname> <given-names>G</given-names></name></person-group>. <article-title>Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis</article-title>. <source>J Atheroscler Thromb</source> (<year>2013</year>) <volume>20</volume>:<fpage>19281</fpage>. [Epub ahead of print].<pub-id pub-id-type="doi">10.5551/jat.19281</pub-id><pub-id pub-id-type="pmid">23965492</pub-id></citation></ref>
<ref id="B120"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eberle</surname> <given-names>C</given-names></name> <name><surname>Merki</surname> <given-names>E</given-names></name> <name><surname>Yamashita</surname> <given-names>T</given-names></name> <name><surname>Johnson</surname> <given-names>S</given-names></name> <name><surname>Armando</surname> <given-names>AM</given-names></name> <name><surname>Quehenberger</surname> <given-names>O</given-names></name> <etal/></person-group> <article-title>Maternal immunization affects in utero programming of insulin resistance and type 2 diabetes</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>(<issue>9</issue>):<fpage>e45361</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0045361</pub-id><pub-id pub-id-type="pmid">23028961</pub-id></citation></ref>
<ref id="B121"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossmann</surname> <given-names>A</given-names></name> <name><surname>Henderson</surname> <given-names>B</given-names></name> <name><surname>Heidecker</surname> <given-names>B</given-names></name> <name><surname>Seiler</surname> <given-names>R</given-names></name> <name><surname>Fraedrich</surname> <given-names>G</given-names></name> <name><surname>Singh</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>T-cells from advanced atherosclerotic lesions recognize hHSP60 and have a restricted T-cell receptor repertoire</article-title>. <source>Exp Gerontol</source> (<year>2008</year>) <volume>43</volume>(<issue>3</issue>):<fpage>229</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1016/j.exger.2007.11.009</pub-id><pub-id pub-id-type="pmid">18226869</pub-id></citation></ref>
<ref id="B122"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knoflach</surname> <given-names>M</given-names></name> <name><surname>Kiechl</surname> <given-names>S</given-names></name> <name><surname>Mayrl</surname> <given-names>B</given-names></name> <name><surname>Kind</surname> <given-names>M</given-names></name> <name><surname>Gaston</surname> <given-names>JS</given-names></name> <name><surname>van der Zee</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis</article-title>. <source>Atherosclerosis</source> (<year>2007</year>) <volume>195</volume>(<issue>2</issue>):<fpage>333</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.09.021</pub-id><pub-id pub-id-type="pmid">17070529</pub-id></citation></ref>
<ref id="B123"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Q</given-names></name> <name><surname>Willeit</surname> <given-names>J</given-names></name> <name><surname>Marosi</surname> <given-names>M</given-names></name> <name><surname>Kleindienst</surname> <given-names>R</given-names></name> <name><surname>Oberhollenzer</surname> <given-names>F</given-names></name> <name><surname>Kiechl</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis</article-title>. <source>Lancet</source> (<year>1993</year>) <volume>341</volume>(<issue>8840</issue>):<fpage>255</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/0140-6736(93)92613-X</pub-id><pub-id pub-id-type="pmid">8093914</pub-id></citation></ref>
<ref id="B124"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Kjellman</surname> <given-names>B</given-names></name> <name><surname>Gidlund</surname> <given-names>M</given-names></name> <name><surname>Andersson</surname> <given-names>B</given-names></name> <name><surname>Jindal</surname> <given-names>S</given-names></name> <name><surname>Kiessling</surname> <given-names>R</given-names></name></person-group>. <article-title>Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein</article-title>. <source>Atherosclerosis</source> (<year>1996</year>) <volume>121</volume>(<issue>1</issue>):<fpage>93</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1016/0021-9150(95)05706-4</pub-id><pub-id pub-id-type="pmid">8678928</pub-id></citation></ref>
<ref id="B125"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname> <given-names>J</given-names></name> <name><surname>Lemne</surname> <given-names>C</given-names></name> <name><surname>Andersson</surname> <given-names>B</given-names></name> <name><surname>van der Zee</surname> <given-names>R</given-names></name> <name><surname>Kiessling</surname> <given-names>R</given-names></name> <name><surname>de Faire</surname> <given-names>U</given-names></name></person-group>. <article-title>Association of serum antibodies to heat-shock protein 65 with borderline hypertension</article-title>. <source>Hypertension</source> (<year>1997</year>) <volume>29</volume>(<issue>1 Pt 1</issue>):<fpage>40</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1161/01.HYP.29.1.40</pub-id><pub-id pub-id-type="pmid">9039077</pub-id></citation></ref>
<ref id="B126"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname> <given-names>ME</given-names></name> <name><surname>Campbell</surname> <given-names>LA</given-names></name></person-group>. <article-title>Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis</article-title>. <source>Thromb Haemost</source> (<year>2011</year>) <volume>106</volume>(<issue>5</issue>):<fpage>858</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1160/TH11-06-0392</pub-id><pub-id pub-id-type="pmid">22012133</pub-id></citation></ref>
<ref id="B127"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shor</surname> <given-names>A</given-names></name> <name><surname>Kuo</surname> <given-names>CC</given-names></name> <name><surname>Patton</surname> <given-names>DL</given-names></name></person-group>. <article-title>Detection of <italic>Chlamydia pneumoniae</italic> in coronary arterial fatty streaks and atheromatous plaques</article-title>. <source>S Afr Med J</source> (<year>1992</year>) <volume>82</volume>(<issue>3</issue>):<fpage>158</fpage>&#x02013;<lpage>61</lpage>.</citation></ref>
<ref id="B128"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saikku</surname> <given-names>P</given-names></name> <name><surname>Leinonen</surname> <given-names>M</given-names></name> <name><surname>Mattila</surname> <given-names>K</given-names></name> <name><surname>Ekman</surname> <given-names>MR</given-names></name> <name><surname>Nieminen</surname> <given-names>MS</given-names></name> <name><surname>Makela</surname> <given-names>PH</given-names></name> <etal/></person-group> <article-title>Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction</article-title>. <source>Lancet</source> (<year>1988</year>) <volume>2</volume>(<issue>8618</issue>):<fpage>983</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(88)90741-6</pub-id><pub-id pub-id-type="pmid">2902492</pub-id></citation></ref>
<ref id="B129"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puolakkainen</surname> <given-names>M</given-names></name> <name><surname>Kuo</surname> <given-names>CC</given-names></name> <name><surname>Shor</surname> <given-names>A</given-names></name> <name><surname>Wang</surname> <given-names>SP</given-names></name> <name><surname>Grayston</surname> <given-names>JT</given-names></name> <name><surname>Campbell</surname> <given-names>LA</given-names></name></person-group>. <article-title>Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques</article-title>. <source>J Clin Microbiol</source> (<year>1993</year>) <volume>31</volume>(<issue>8</issue>):<fpage>2212</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">8370753</pub-id></citation></ref>
<ref id="B130"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saikku</surname> <given-names>P</given-names></name> <name><surname>Leinonen</surname> <given-names>M</given-names></name> <name><surname>Tenkanen</surname> <given-names>L</given-names></name> <name><surname>Linnanmaki</surname> <given-names>E</given-names></name> <name><surname>Ekman</surname> <given-names>MR</given-names></name> <name><surname>Manninen</surname> <given-names>V</given-names></name> <etal/></person-group> <article-title>Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study</article-title>. <source>Ann Intern Med</source> (<year>1992</year>) <volume>116</volume>(<issue>4</issue>):<fpage>273</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.7326/0003-4819-116-4-273</pub-id><pub-id pub-id-type="pmid">1733381</pub-id></citation></ref>
<ref id="B131"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connor</surname> <given-names>CM</given-names></name> <name><surname>Dunne</surname> <given-names>MW</given-names></name> <name><surname>Pfeffer</surname> <given-names>MA</given-names></name> <name><surname>Muhlestein</surname> <given-names>JB</given-names></name> <name><surname>Yao</surname> <given-names>L</given-names></name> <name><surname>Gupta</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial</article-title>. <source>JAMA</source> (<year>2003</year>) <volume>290</volume>(<issue>11</issue>):<fpage>1459</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1001/jama.290.11.1459</pub-id><pub-id pub-id-type="pmid">13129985</pub-id></citation></ref>
<ref id="B132"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grayston</surname> <given-names>JT</given-names></name> <name><surname>Kronmal</surname> <given-names>RA</given-names></name> <name><surname>Jackson</surname> <given-names>LA</given-names></name> <name><surname>Parisi</surname> <given-names>AF</given-names></name> <name><surname>Muhlestein</surname> <given-names>JB</given-names></name> <name><surname>Cohen</surname> <given-names>JD</given-names></name> <etal/></person-group> <article-title>Azithromycin for the secondary prevention of coronary events</article-title>. <source>N Engl J Med</source> (<year>2005</year>) <volume>352</volume>(<issue>16</issue>):<fpage>1637</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa043526</pub-id><pub-id pub-id-type="pmid">15843666</pub-id></citation></ref>
<ref id="B133"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname> <given-names>CP</given-names></name> <name><surname>Braunwald</surname> <given-names>E</given-names></name> <name><surname>McCabe</surname> <given-names>CH</given-names></name> <name><surname>Grayston</surname> <given-names>JT</given-names></name> <name><surname>Muhlestein</surname> <given-names>B</given-names></name> <name><surname>Giugliano</surname> <given-names>RP</given-names></name> <etal/></person-group> <article-title>Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome</article-title>. <source>N Engl J Med</source> (<year>2005</year>) <volume>352</volume>(<issue>16</issue>):<fpage>1646</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa043528</pub-id><pub-id pub-id-type="pmid">15843667</pub-id></citation></ref>
<ref id="B134"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lockhart</surname> <given-names>PB</given-names></name> <name><surname>Bolger</surname> <given-names>AF</given-names></name> <name><surname>Papapanou</surname> <given-names>PN</given-names></name> <name><surname>Osinbowale</surname> <given-names>O</given-names></name> <name><surname>Trevisan</surname> <given-names>M</given-names></name> <name><surname>Levison</surname> <given-names>ME</given-names></name> <etal/></person-group> <article-title>Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association? A scientific statement from the American Heart Association</article-title>. <source>Circulation</source> (<year>2012</year>) <volume>125</volume>(<issue>20</issue>):<fpage>2520</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1161/CIR.0b013e31825719f3</pub-id><pub-id pub-id-type="pmid">22514251</pub-id></citation></ref>
<ref id="B135"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname> <given-names>IL</given-names></name> <name><surname>Genco</surname> <given-names>R</given-names></name></person-group>. <article-title>Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases</article-title>. <source>J Clin Periodontol</source> (<year>2013</year>) <volume>40</volume> <issue>Suppl 14</issue>:<fpage>S106</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1111/jcpe.12077</pub-id></citation></ref>
<ref id="B136"><label>136</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname> <given-names>K</given-names></name> <name><surname>Petro</surname> <given-names>BJ</given-names></name> <name><surname>Shlimon</surname> <given-names>AE</given-names></name> <name><surname>Unterman</surname> <given-names>TG</given-names></name></person-group>. <article-title>Effect of periodontitis on insulin resistance and the onset of type 2 diabetes mellitus in Zucker diabetic fatty rats</article-title>. <source>J Periodontol</source> (<year>2008</year>) <volume>79</volume>(<issue>7</issue>):<fpage>1208</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1902/jop.2008.070605</pub-id><pub-id pub-id-type="pmid">18597603</pub-id></citation></ref>
<ref id="B137"><label>137</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Preshaw</surname> <given-names>PM</given-names></name> <name><surname>Alba</surname> <given-names>AL</given-names></name> <name><surname>Herrera</surname> <given-names>D</given-names></name> <name><surname>Jepsen</surname> <given-names>S</given-names></name> <name><surname>Konstantinidis</surname> <given-names>A</given-names></name> <name><surname>Makrilakis</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Periodontitis and diabetes: a two-way relationship</article-title>. <source>Diabetologia</source> (<year>2012</year>) <volume>55</volume>(<issue>1</issue>):<fpage>21</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-011-2342-y</pub-id></citation></ref>
<ref id="B138"><label>138</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fateh-Moghadam</surname> <given-names>S</given-names></name> <name><surname>Bocksch</surname> <given-names>W</given-names></name> <name><surname>Wessely</surname> <given-names>R</given-names></name> <name><surname>Jager</surname> <given-names>G</given-names></name> <name><surname>Hetzer</surname> <given-names>R</given-names></name> <name><surname>Gawaz</surname> <given-names>M</given-names></name></person-group>. <article-title>Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy</article-title>. <source>Transplantation</source> (<year>2003</year>) <volume>76</volume>(<issue>10</issue>):<fpage>1470</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1097/01.TP.0000090163.48433.48</pub-id><pub-id pub-id-type="pmid">14657688</pub-id></citation></ref>
<ref id="B139"><label>139</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melnick</surname> <given-names>JL</given-names></name> <name><surname>Hu</surname> <given-names>C</given-names></name> <name><surname>Burek</surname> <given-names>J</given-names></name> <name><surname>Adam</surname> <given-names>E</given-names></name> <name><surname>DeBakey</surname> <given-names>ME</given-names></name></person-group>. <article-title>Cytomegalovirus DNA in arterial walls of patients with atherosclerosis</article-title>. <source>J Med Virol</source> (<year>1994</year>) <volume>42</volume>(<issue>2</issue>):<fpage>170</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1002/jmv.1890420213</pub-id><pub-id pub-id-type="pmid">8158112</pub-id></citation></ref>
<ref id="B140"><label>140</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Streblow</surname> <given-names>DN</given-names></name> <name><surname>Soderberg-Naucler</surname> <given-names>C</given-names></name> <name><surname>Vieira</surname> <given-names>J</given-names></name> <name><surname>Smith</surname> <given-names>P</given-names></name> <name><surname>Wakabayashi</surname> <given-names>E</given-names></name> <name><surname>Ruchti</surname> <given-names>F</given-names></name> <etal/></person-group> <article-title>The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration</article-title>. <source>Cell</source> (<year>1999</year>) <volume>99</volume>(<issue>5</issue>):<fpage>511</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81539-1</pub-id><pub-id pub-id-type="pmid">10589679</pub-id></citation></ref>
<ref id="B141"><label>141</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname> <given-names>AF</given-names></name> <name><surname>Mendall</surname> <given-names>MA</given-names></name> <name><surname>Kaski</surname> <given-names>JC</given-names></name> <name><surname>Edger</surname> <given-names>TM</given-names></name> <name><surname>Risley</surname> <given-names>P</given-names></name> <name><surname>Poloniecki</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA)</article-title>. <source>Circulation</source> (<year>2002</year>) <volume>106</volume>(<issue>10</issue>):<fpage>1219</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000027820.66786.CF</pub-id><pub-id pub-id-type="pmid">12208796</pub-id></citation></ref>
<ref id="B142"><label>142</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mach</surname> <given-names>F</given-names></name> <name><surname>Sukhova</surname> <given-names>GK</given-names></name> <name><surname>Michetti</surname> <given-names>M</given-names></name> <name><surname>Libby</surname> <given-names>P</given-names></name> <name><surname>Michetti</surname> <given-names>P</given-names></name></person-group>. <article-title>Influence of Helicobacter pylori infection during atherogenesis in vivo in mice</article-title>. <source>Circ Res</source> (<year>2002</year>) <volume>90</volume>(<issue>1</issue>):<fpage>E1</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1161/hh0102.102270</pub-id><pub-id pub-id-type="pmid">11786527</pub-id></citation></ref>
<ref id="B143"><label>143</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volzke</surname> <given-names>H</given-names></name> <name><surname>Wolff</surname> <given-names>B</given-names></name> <name><surname>Ludemann</surname> <given-names>J</given-names></name> <name><surname>Guertler</surname> <given-names>L</given-names></name> <name><surname>Kramer</surname> <given-names>A</given-names></name> <name><surname>John</surname> <given-names>U</given-names></name> <name><surname>Felix</surname> <given-names>SB</given-names></name></person-group>. <article-title>Seropositivity for anti-Borrelia IgG antibody is independently associated with carotid atherosclerosis</article-title>. <source>Atherosclerosis</source> (<year>2006</year>) <volume>184</volume>(<issue>1</issue>):<fpage>108</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.10.048</pub-id><pub-id pub-id-type="pmid">16326170</pub-id></citation></ref>
<ref id="B144"><label>144</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toplak</surname> <given-names>H</given-names></name> <name><surname>Haller</surname> <given-names>EM</given-names></name> <name><surname>Lauermann</surname> <given-names>T</given-names></name> <name><surname>Weber</surname> <given-names>K</given-names></name> <name><surname>Bahadori</surname> <given-names>B</given-names></name> <name><surname>Reisinger</surname> <given-names>EC</given-names></name> <etal/></person-group> <article-title>Increased prevalence of IgA-Chlamydia antibodies in NIDDM patients</article-title>. <source>Diabetes Res Clin Pract</source> (<year>1996</year>) <volume>32</volume>(<issue>1-2</issue>):<fpage>97</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="doi">10.1016/0168-8227(96)01216-8</pub-id><pub-id pub-id-type="pmid">8803487</pub-id></citation></ref>
<ref id="B145"><label>145</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkind</surname> <given-names>MS</given-names></name></person-group>. <article-title>Infectious burden: a new risk factor and treatment target for atherosclerosis</article-title>. <source>Infect Disord Drug Targets</source> (<year>2012</year>) <volume>10</volume>(<issue>2</issue>):<fpage>84</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.2174/187152610790963519</pub-id><pub-id pub-id-type="pmid">20166973</pub-id></citation></ref>
<ref id="B146"><label>146</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>M</given-names></name> <name><surname>Guerra</surname> <given-names>N</given-names></name> <name><surname>Sukhova</surname> <given-names>GK</given-names></name> <name><surname>Yang</surname> <given-names>K</given-names></name> <name><surname>Miller</surname> <given-names>CK</given-names></name> <name><surname>Shi</surname> <given-names>GP</given-names></name> <etal/></person-group> <article-title>Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis</article-title>. <source>Circulation</source> (<year>2011</year>) <volume>124</volume>(<issue>25</issue>):<fpage>2933</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.034850</pub-id><pub-id pub-id-type="pmid">22104546</pub-id></citation></ref>
<ref id="B147"><label>147</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dandona</surname> <given-names>P</given-names></name> <name><surname>Aljada</surname> <given-names>A</given-names></name> <name><surname>Bandyopadhyay</surname> <given-names>A</given-names></name></person-group>. <article-title>Inflammation: the link between insulin resistance, obesity and diabetes</article-title>. <source>Trends Immunol</source> (<year>2004</year>) <volume>25</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2003.10.013</pub-id><pub-id pub-id-type="pmid">14698276</pub-id></citation></ref>
<ref id="B148"><label>148</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haeggstrom</surname> <given-names>JZ</given-names></name> <name><surname>Funk</surname> <given-names>CD</given-names></name></person-group>. <article-title>Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease</article-title>. <source>Chem Rev</source> (<year>2011</year>) <volume>111</volume>(<issue>10</issue>):<fpage>5866</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1021/cr200246d</pub-id></citation></ref>
<ref id="B149"><label>149</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname> <given-names>H</given-names></name> <name><surname>Gabrielsen</surname> <given-names>A</given-names></name> <name><surname>Agardh</surname> <given-names>HE</given-names></name> <name><surname>Wan</surname> <given-names>M</given-names></name> <name><surname>Wetterholm</surname> <given-names>A</given-names></name> <name><surname>Wong</surname> <given-names>CH</given-names></name> <etal/></person-group> <article-title>Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2006</year>) <volume>103</volume>(<issue>21</issue>):<fpage>8161</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0602414103</pub-id><pub-id pub-id-type="pmid">16698924</pub-id></citation></ref>
<ref id="B150"><label>150</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manzi</surname> <given-names>S</given-names></name> <name><surname>Meilahn</surname> <given-names>EN</given-names></name> <name><surname>Rairie</surname> <given-names>JE</given-names></name> <name><surname>Conte</surname> <given-names>CG</given-names></name> <name><surname>Medsger</surname> <given-names>TA</given-names> <suffix>Jr</suffix></name> <name><surname>Jansen-McWilliams</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study</article-title>. <source>Am J Epidemiol</source> (<year>1997</year>) <volume>145</volume>(<issue>5</issue>):<fpage>408</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a009122</pub-id><pub-id pub-id-type="pmid">9048514</pub-id></citation></ref>
<ref id="B151"><label>151</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wajchenberg</surname> <given-names>BL</given-names></name> <name><surname>Feitosa</surname> <given-names>AC</given-names></name> <name><surname>Rassi</surname> <given-names>N</given-names></name> <name><surname>Lerario</surname> <given-names>AC</given-names></name> <name><surname>Betti</surname> <given-names>RT</given-names></name></person-group>. <article-title>Glycemia and cardiovascular disease in type 1 diabetes mellitus</article-title>. <source>Endocr Pract</source> (<year>2008</year>) <volume>14</volume>(<issue>7</issue>):<fpage>912</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.4158/EP.14.7.912</pub-id><pub-id pub-id-type="pmid">18996824</pub-id></citation></ref>
<ref id="B152"><label>152</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Lorgeril</surname> <given-names>M</given-names></name> <name><surname>Hamazaki</surname> <given-names>T</given-names></name> <name><surname>Kostucki</surname> <given-names>W</given-names></name> <name><surname>Okuyama</surname> <given-names>H</given-names></name> <name><surname>Pavy</surname> <given-names>B</given-names></name> <name><surname>McGill</surname> <given-names>AT</given-names></name> <etal/></person-group> <article-title>Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review</article-title>. <source>Rev Recent Clin Trials</source> (<year>2012</year>) <volume>7</volume>(<issue>2</issue>):<fpage>150</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.2174/157488712800100279</pub-id><pub-id pub-id-type="pmid">22353198</pub-id></citation></ref>
<ref id="B153"><label>153</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>MA</given-names></name> <name><surname>Gallo</surname> <given-names>RM</given-names></name> <name><surname>Renukaradhya</surname> <given-names>GJ</given-names></name> <name><surname>Du</surname> <given-names>W</given-names></name> <name><surname>Gervay-Hague</surname> <given-names>J</given-names></name> <name><surname>Brutkiewicz</surname> <given-names>RR</given-names></name></person-group>. <article-title>Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>(<issue>8</issue>):<fpage>4744</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0804311</pub-id><pub-id pub-id-type="pmid">19342651</pub-id></citation></ref>
<ref id="B154"><label>154</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>CY</given-names></name> <name><surname>Liu</surname> <given-names>PY</given-names></name> <name><surname>Liao</surname> <given-names>JK</given-names></name></person-group>. <article-title>Pleiotropic effects of statin therapy: molecular mechanisms and clinical results</article-title>. <source>Trends Mol Med</source> (<year>2008</year>) <volume>14</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmed.2007.11.004</pub-id><pub-id pub-id-type="pmid">18068482</pub-id></citation></ref>
<ref id="B155"><label>155</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname> <given-names>PM</given-names></name> <name><surname>Danielson</surname> <given-names>E</given-names></name> <name><surname>Fonseca</surname> <given-names>FA</given-names></name> <name><surname>Genest</surname> <given-names>J</given-names></name> <name><surname>Gotto</surname> <given-names>AM</given-names> <suffix>Jr</suffix></name> <name><surname>Kastelein</surname> <given-names>JJ</given-names></name> <etal/></person-group> <article-title>Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein</article-title>. <source>N Engl J Med</source> (<year>2008</year>) <volume>359</volume>(<issue>21</issue>):<fpage>2195</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa0807646</pub-id></citation></ref>
<ref id="B156"><label>156</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname> <given-names>PM</given-names></name></person-group>. <article-title>Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?</article-title> <source>Curr Atheroscler Rep</source> (<year>2013</year>) <volume>15</volume>(<issue>1</issue>):<fpage>295</fpage>.<pub-id pub-id-type="doi">10.1007/s11883-012-0295-3</pub-id><pub-id pub-id-type="pmid">23225175</pub-id></citation></ref>
<ref id="B157"><label>157</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Micha</surname> <given-names>R</given-names></name> <name><surname>Imamura</surname> <given-names>F</given-names></name> <name><surname>Wyler von Ballmoos</surname> <given-names>M</given-names></name> <name><surname>Solomon</surname> <given-names>DH</given-names></name> <name><surname>Hernan</surname> <given-names>MA</given-names></name> <name><surname>Ridker</surname> <given-names>PM</given-names></name> <etal/></person-group> <article-title>Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease</article-title>. <source>Am J Cardiol</source> (<year>2011</year>) <volume>108</volume>(<issue>9</issue>):<fpage>1362</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2011.06.054</pub-id><pub-id pub-id-type="pmid">21855836</pub-id></citation></ref>
<ref id="B158"><label>158</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bulgarelli</surname> <given-names>A</given-names></name> <name><surname>Martins Dias</surname> <given-names>AA</given-names></name> <name><surname>Caramelli</surname> <given-names>B</given-names></name> <name><surname>Maranhao</surname> <given-names>RC</given-names></name></person-group>. <article-title>Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits</article-title>. <source>J Cardiovasc Pharmacol</source> (<year>2012</year>) <volume>59</volume>(<issue>4</issue>):<fpage>308</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1097/FJC.0b013e318241c385</pub-id><pub-id pub-id-type="pmid">22113347</pub-id></citation></ref>
<ref id="B159"><label>159</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname> <given-names>E</given-names></name> <name><surname>Lingala</surname> <given-names>VB</given-names></name> <name><surname>Singh</surname> <given-names>G</given-names></name></person-group>. <article-title>Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis</article-title>. <source>Circulation</source> (<year>2004</year>) <volume>110</volume>(<issue>13</issue>):<fpage>1774</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000142864.83780.81</pub-id><pub-id pub-id-type="pmid">15381644</pub-id></citation></ref>
<ref id="B160"><label>160</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernatsky</surname> <given-names>S</given-names></name> <name><surname>Hudson</surname> <given-names>M</given-names></name> <name><surname>Suissa</surname> <given-names>S</given-names></name></person-group>. <article-title>Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source> (<year>2005</year>) <volume>44</volume>(<issue>5</issue>):<fpage>677</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/keh610</pub-id><pub-id pub-id-type="pmid">15784627</pub-id></citation></ref>
<ref id="B161"><label>161</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qamar</surname> <given-names>A</given-names></name> <name><surname>Rader</surname> <given-names>DJ</given-names></name></person-group>. <article-title>Effect of interleukin 1beta inhibition in cardiovascular disease</article-title>. <source>Curr Opin Lipidol</source> (<year>2012</year>) <volume>23</volume>(<issue>6</issue>):<fpage>548</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1097/MOL.0b013e328359b0a6</pub-id><pub-id pub-id-type="pmid">23069985</pub-id></citation></ref>
<ref id="B162"><label>162</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subbanagounder</surname> <given-names>G</given-names></name> <name><surname>Leitinger</surname> <given-names>N</given-names></name> <name><surname>Shih</surname> <given-names>PT</given-names></name> <name><surname>Faull</surname> <given-names>KF</given-names></name> <name><surname>Berliner</surname> <given-names>JA</given-names></name></person-group>. <article-title>Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086</article-title>. <source>Circ Res</source> (<year>1999</year>) <volume>85</volume>(<issue>4</issue>):<fpage>311</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1161/01.RES.85.4.311</pub-id><pub-id pub-id-type="pmid">10455059</pub-id></citation></ref>
<ref id="B163"><label>163</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ewing</surname> <given-names>MM</given-names></name> <name><surname>de Vries</surname> <given-names>MR</given-names></name> <name><surname>Nordzell</surname> <given-names>M</given-names></name> <name><surname>Pettersson</surname> <given-names>K</given-names></name> <name><surname>de Boer</surname> <given-names>HC</given-names></name> <name><surname>van Zonneveld</surname> <given-names>AJ</given-names></name> <etal/></person-group> <article-title>Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2011</year>) <volume>31</volume>(<issue>1</issue>):<fpage>95</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.110.216747</pub-id><pub-id pub-id-type="pmid">20947818</pub-id></citation></ref>
<ref id="B164"><label>164</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donoghue</surname> <given-names>ML</given-names></name> <name><surname>Braunwald</surname> <given-names>E</given-names></name> <name><surname>White</surname> <given-names>HD</given-names></name> <name><surname>Serruys</surname> <given-names>P</given-names></name> <name><surname>Steg</surname> <given-names>PG</given-names></name> <name><surname>Hochman</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Study design and rationale for the stabilization of plaques using darapladib-thrombolysis in myocardial infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome</article-title>. <source>Am Heart J</source> (<year>2011</year>) <volume>162</volume>(<issue>4</issue>):<fpage>613&#x02013;19.e611</fpage>.<pub-id pub-id-type="doi">10.1016/j.ahj.2011.07.018</pub-id><pub-id pub-id-type="pmid">21982651</pub-id></citation></ref>
<ref id="B165"><label>165</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fredrikson</surname> <given-names>GN</given-names></name> <name><surname>Soderberg</surname> <given-names>I</given-names></name> <name><surname>Lindholm</surname> <given-names>M</given-names></name> <name><surname>Dimayuga</surname> <given-names>P</given-names></name> <name><surname>Chyu</surname> <given-names>KY</given-names></name> <name><surname>Shah</surname> <given-names>PK</given-names></name> <etal/></person-group> <article-title>Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2003</year>) <volume>23</volume>(<issue>5</issue>):<fpage>879</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1161/01.ATV.0000067937.93716.DB</pub-id><pub-id pub-id-type="pmid">12649092</pub-id></citation></ref>
<ref id="B166"><label>166</label><citation citation-type="web"><source>BioInvent Announces Data From BI-204 Phase IIa Study on Stable Atherosclerotic Vascular Disease</source> (<year>2012</year>). Available from: <uri xlink:href="http://www.news-medical.net/news/20120711/BioInvent-announces-data-from-BI-204-phase-IIa-study-on-stable-atherosclerotic-vascular-disease.aspx">http://www.news-medical.net/news/20120711/BioInvent-announces-data-from-BI-204-phase-IIa-study-on-stable-atherosclerotic-vascular-disease.aspx</uri></citation></ref>
<ref id="B167"><label>167</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name> <name><surname>Khanna</surname> <given-names>S</given-names></name> <name><surname>Goodyear</surname> <given-names>CS</given-names></name> <name><surname>Park</surname> <given-names>YB</given-names></name> <name><surname>Raz</surname> <given-names>E</given-names></name> <name><surname>Thiel</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>(<issue>2</issue>):<fpage>1346</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0900948</pub-id><pub-id pub-id-type="pmid">19564341</pub-id></citation></ref>
<ref id="B168"><label>168</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicoletti</surname> <given-names>A</given-names></name> <name><surname>Kaveri</surname> <given-names>S</given-names></name> <name><surname>Caligiuri</surname> <given-names>G</given-names></name> <name><surname>Bariety</surname> <given-names>J</given-names></name> <name><surname>Hansson</surname> <given-names>GK</given-names></name></person-group>. <article-title>Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice</article-title>. <source>J Clin Invest</source> (<year>1998</year>) <volume>102</volume>(<issue>5</issue>):<fpage>910</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1172/JCI119892</pub-id></citation></ref>
<ref id="B169"><label>169</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname> <given-names>J</given-names></name> <name><surname>Lin</surname> <given-names>J</given-names></name> <name><surname>Yang</surname> <given-names>X</given-names></name> <name><surname>Yuan</surname> <given-names>D</given-names></name> <name><surname>Wu</surname> <given-names>J</given-names></name> <name><surname>Li</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Nasal immunization with different forms of heat shock protein-65 reduced high-cholesterol-diet-driven rabbit atherosclerosis</article-title>. <source>Int Immunopharmacol</source> (<year>2012</year>) <volume>13</volume>(<issue>1</issue>):<fpage>82</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.intimp.2012.03.008</pub-id><pub-id pub-id-type="pmid">22465386</pub-id></citation></ref>
<ref id="B170"><label>170</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murshid</surname> <given-names>A</given-names></name> <name><surname>Gong</surname> <given-names>J</given-names></name> <name><surname>Calderwood</surname> <given-names>SK</given-names></name></person-group>. <article-title>The role of heat shock proteins in antigen cross presentation</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>3</volume>:<fpage>63</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00063</pub-id></citation></ref>
</ref-list>
</back>
</article>